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 ABSTRACT 
Utilizing early cellular changes to explore biological responses to individual chemical 
and mixture exposures 
by 
Julie Anne Vrana 
 Humans are continuously exposed to a vast number of chemicals, whether it be 
from the air we breathe, the water we drink, or the medications we take daily. Early 
cellular changes after exposure to chemical insult, both individual chemicals and 
mixtures (two or more chemicals) thereof, can offer a wealth of information about 
cellular adaptation (e.g., cell death or survival decision processes). From this 
understanding, better prediction models for chemical risk assessment, such as toxicity or 
carcinogenicity, can be elucidated. Further, these prediction models can greatly improve 
the large backlog of chemicals waiting to be evaluated for potential adverse effects. One 
approach to understand cellular changes and responses after chemical or mixture 
exposure is with toxicodynamics. From a toxicodynamic approach, a host of information 
can be determined, such as spatiotemporal interactions of chemical insult with biological 
targets, the corresponding disruption of intracellular pathways and bioenergetics, and 
downstream effects after exposure. Appropriately measuring these dynamic cellular 
changes is imperative. The recent advances in molecular biology, high-throughput in 
vitro screening assays, and numerous computational techniques have allowed 
toxicologists to collect large data sets on signaling pathways that are perturbed in 
response to chemical insults. From these early cellular perturbations, whether they be 
signaling proteins, biomolecules (e.g., ATP, hormones, NADH), or ions (e.g., Ca
2+
 or 
K
+
), in response to a wide range of doses, especially low concentrations, improved risk 
assessment prediction models for individual chemical and mixture exposures can be 
utilized by many fields, such as risk assessment for environmental toxicology and target 
molecule/pathway analysis for drug development and pharmacology.  
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Chapter 1 
Introduction to early cellular changes that may contribute to 
individual and mixture responses after exposure 
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1. Introduction: Utilizing early cellular changes to explore biological responses to 
individual and chemical mixtures 
 The early cellular changes initiated by external stimuli (whether that be chemical, 
physical, or biological agents) can offer a host of information about the adaptive response 
and adverse effects related to individual chemical and mixture exposures. Notable 
examples of early cellular changes are perturbations of dynamic intracellular signaling 
networks and alterations in cellular bioenergetics, such as increased/decreased oxygen 
consumption or electron transport chain uncoupling. Due to the interconnectivity of 
various effector proteins and biomolecules, activity at a distinct intracellular location can 
have consequences at distal locations.  Additionally, as the primary tenet of toxicology 
proclaims, “it is the dose that makes the poison,” a better understanding of cellular 
changes in response to a range of concentrations, especially low dose exposures, is 
essential to toxicity testing and chemical risk assessment. Finally, the ability to measure 
the rapid and dynamic cellular responses to exposure is critical for an enhanced 
understanding of toxicity. The experimental conditions and assays capable of capturing 
relevant mechanistic information for toxicity testing will be discussed in this chapter. A 
better understanding of the mechanistic components related to chemical response has 
numerous implications across many fields, such as risk assessment for toxicology and 
target molecule/pathway analysis for drug development and pharmacology. With 
mechanistic data collected from various doses, intracellular proteins and biomolecules, 
and cellular endpoints, better toxicity prediction models can be developed for individual 
chemical and mixtures risk assessment.   
 
3 
 
1.1 Classification of toxic agent and exposure effects - a toxicological perspective 
 Humans are continuously exposed to a plethora of chemicals daily. These 
chemicals can be traced to a variety of sources, such as environmental, pharmaceutical, or 
industrial. With the considerable amount of individual chemicals humans can be exposed 
to on a daily basis, this begs the question, what classifies a chemical or agent as "toxic"? 
A toxic agent, whether it be chemical, biological, or physical, can be classified by their 
use (e.g., pharmaceutical, pesticide, additive, etc.), source (e.g., human-made, plant or 
animal toxin, etc.), target organ(s) (e.g., brain, liver, heart, etc.), and effects (e.g., 
cardiotoxicity, carcinogenicity, immunogenicity, etc.) (Casarett and Klaassen, 2008). A 
primary tenet of toxicology states that all chemical agents are toxic, but it is the dose that 
determines if an agent is toxic or safe (Pottenger and Gollapudi, 2009). The classification 
of what constitutes an agent as toxic, and the threshold thereof, can be ambiguous. 
However, the experimental characterization of an agent that incorporates chemical 
properties and biological exposure effects is useful for toxicological risk assessment. The 
work described in this dissertation will primarily focus on exogenous chemical stressors, 
also known as xenobiotics.  
  Appropriately characterizing biological effects of a single agent exposure can be 
a daunting task. Toxicological risk assessment determines the quantitative estimate of 
possible effects of a xenobiotic on human health (Casarett and Klaassen, 2008). 
Following exposure, xenobiotic effects can be adverse, deleterious, or dangerous to an 
organism (Edwards and Aronson, 2000). Conversely, some effects can be beneficial, such 
as pharmaceutical side effects of antihistamines (drowsiness) or oral contraceptives 
(decrease acne severity). To properly address the adverse or beneficial nature of a 
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chemical exposure, the dose and time course of toxicity/adaptation needs to be 
elucidated.   
 
1.1.1 Dose-response for chemical exposure toxicity testing and risk assessment 
 One of the most central concepts utilized for toxicity studies and risk assessment 
is the dose-response relationship (Calabrese and Baldwin, 2003b). The response variable 
can be any desired effect to be measured, such as cell death, survival, or cellular oxygen 
consumption, and the independent variable would be the doses required to elicit a 
response. There are many types of dose-response models used in toxicity testing, but the 
most dominant is the threshold model (Calabrese and Baldwin, 2003a). The threshold 
model has been used in many scientific disciplines, such as biology, pharmacology, and 
toxicology, and has been the primary model for regulatory agencies, such as the U.S. 
Federal Drug Administration (FDA) and Environmental Protection Agency (EPA) 
(Calabrese and Baldwin, 2003a). In the threshold model, depending upon the effect 
measured and assay sensitivity, there exists a dose below which the probability of a 
measured response for a sample or individual compared to control is zero (Cox, 1987). 
This threshold dose is also referred to as the no observed adverse effect level (NOAEL) 
(Allen et al., 1994). An alternative model, the hormesis model, has also proven to be 
useful for low-dose (below the NOAEL) risk assessment (Calabrese, 2009) and has seen 
a recent surge in interest due to advances in molecular toxicology testing (Calabrese and 
Baldwin, 2003b). The hormesis model is a biphasic dose-response relationship and can be 
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succinctly described as low dose activation followed by high dose inhibition, which can 
appear as a U-shaped or J-shaped dose-response curve (Calabrese, 2008).  
 The renewed interest in hormesis as a valid model for toxicity testing has opened 
the door for low-dose biochemical and molecular toxicology research (Calabrese, 2008). 
It is important to note that the hormetic dose-response should also consider time in 
toxicity testing. This is due to the fact that hormesis responses may be a compensatory 
response that follows the initial disruption in homeostasis, resulting in the characteristic 
low-dose stimulatory response (Calabrese, 2001). Biological systems are highly 
coordinated and dynamic (Kholodenko et al., 2010), the exclusion of temporal response 
in risk assessment modeling would ignore the ability of an organism to adapt and respond 
to a low-dose exposure. Therefore, toxicological risk assessment needs to be inclusive of 
the spatiotemporal aspect of biological response post-exposure as well as a wide range of 
doses, including low doses.      
 
1.1.2 Chemical mixtures  
 Current chemical exposure risk assessment is primarily carried out for single 
xenobiotics (Cedergreen et al., 2008), however, in reality humans are continuously 
exposed to a vast number of components, whether they be chemical, physical, or 
biological agents, at various doses, and through a variety of exposure routes on a daily 
basis (Groten et al., 2001). Understanding and ultimately predicting the possible 
combined effects of a given mixture exposure is necessary for risk assessment 
toxicology.  There are two types of mixtures: simple and complex. Simple mixtures 
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contain a small number of different chemicals and the composition is known. Complex 
mixtures contain hundreds to tens of thousands individual chemicals, of which the 
composition (dose or constituents) is not known (Feron et al., 1998). Experimentally 
determining the effects of all possible mixture combinations, or even binary mixtures, for 
a range of doses at different time points is not physically or financially possible 
(Cedergreen et al., 2008). Therefore, adequate models capable of predicting mixture 
responses are necessary for various sectors, such as pharmacological adverse interaction 
risk assessments and environmental exposure risk assessments. The two most commonly 
used and accepted mixture prediction models are Loewe additivity (dose addition) and 
Bliss independence (response addition) (McCarty and Borgert, 2006). 
    Dose addition is typically used when two or more chemical agents have a 
similar mechanism of action (Borgert et al., 2004). Dose addition is based on the theory 
that two chemicals in a mixture act as a dilution of each other (Loewe and Muischnek, 
1926; Berenbaum, 1989). Traditional dose additivity can be described as shown in 
Equation 1: 
 
     
     
              (1) 
where α' is the dose of the chemical   when administered  as a mixture producing 
response E, and α is the concentration of the chemical agent,  , required to produce the 
response effect E when administered alone (single exposure). Equation 1 can be used for 
n number of agents as a mixture. If the overall expression is < 1, the mixture is 
considered synergistic. Conversely, if the overall expression is > 1, the mixture is 
considered antagonistic (Rajapakse et al., 2001).  
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 Response addition (Bliss independence) is typically used for two (or more) 
chemicals that do not have the same mechanism of action, that is, the organism will 
respond to each chemical agent independently, as though the other agent(s) are not 
present (Bliss, 1939; McCarty and Borgert, 2006). The prediction of mixture effects 
using response addition is equivalent to the conditional sum of independent chemical 
effect probabilities (Boyd et al., 2011). Response addition can be described by the 
expression (equation 2) 
                                 (2) 
where F(  ) is the response effect produced by chemical   at dose α. Since this is a 
probabilistic model, F(  ) cannot be greater than 1. Dose addition and response addition 
models are generalizations of nonlinear regression models, such as a Gompertz growth 
curve or Hill plot, and can be easily compared to observed mixture dose-response curves 
(Rajapakse et al., 2001; Boyd et al., 2011).    
 
1.1.3 Mode of action vs mechanism of action 
 Regulatory guidelines for mixture risk assessments rely heavily on the similarity 
(or dissimilarity) of two chemical components' mechanistic information for model 
selection of a given mixture (USEPA, 1986; USEPA, 1999; USEPA, 2000; ATSDR, 
2001b; ATSDR, 2001a; USEPA, 2002). In this discussion of prediction models for 
mixture toxicity, the term “mechanism of action” is used loosely. The term "mechanism" 
of action is often used interchangeably with "mode" of action (Borgert et al., 2004). 
However, these terms have specific definitions, but are often defined differently 
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depending upon the literature article cited (Aptula and Roberts, 2006; Spurgeon et al., 
2010). Traditionally, "mechanism of action" refers to the series of molecular events from 
the absorption of an effective dose of an agent to the eventual biological response 
(Butterworth et al., 1995). To fully describe the mechanism of action for a chemical, the 
components outlined in Figure 1.1 would need to be determined experimentally. 
 
The term "mode of action" is a more generalized way to describe a chemical's 
action on a given organism (Schlosser and Bogdanffy, 1999). The term "mode of action" 
describes the type of observed response of an organism exposed to a given chemical or 
mixture and may only refer to the significant events or components of the mechanism 
Figure 1.1. Mechanism of action. Schematic outlining the components necessary to 
elucidate the mechanism of action for an exposure. All steps must include the temporal 
and dose components to fully understand mechanism of action for a given chemical or 
mixture exposure.     
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necessary for producing a particular biological response or toxic effect (Dellarco and 
Wiltse, 1998). Regardless of the terminology, the suitability of either model for a given 
experiment or effect prediction remains debatable when thorough mechanisms or modes 
of action are unknown, especially for low dose studies (Jonker et al., 2005; Spurgeon et 
al., 2010). Often, the models fail to predict mixtures toxicity when an observed mixture 
acts synergistically (Meled et al., 1998; Forget et al., 1999), antagonistically (Posthuma 
et al., 1997; Van Gestel and Hensbergen, 1997), or dose-dependent subtle interactions 
(e.g., synergy for low dose mixtures and antagonist for high dose mixtures) (Gennings et 
al., 2002; Jonker et al., 2004). To address these challenges, future model development 
should incorporate low dose (i.e., below the NOAEL) mixtures mechanistic effects on the 
appropriate spatiotemporal scale.    
 
1.2 Early cellular changes post-exposure  
 Understanding and ultimately predicting potential biological effects and health 
outcomes from single chemical or mixture exposure remains an arduous task for risk 
assessment. The predominant approach for toxicity testing relies heavily on whole animal 
studies evaluating observable apical responses, such as clinical effects or pathologic 
changes from high dose exposures (Spurgeon et al., 2010). While many of these studies 
have been thorough, the amount of time and resources required to carry out this low-
throughput methodology has left this approach unable to meet the demands of current 
toxicology needs (NRC, 2007). The enormous backlog of chemicals waiting to be 
evaluated for toxic outcome has inspired a paradigm shift in toxicity testing, proposed by 
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the U.S. National Research Council (NRC) report, Toxicity Testing in the 21st Century: A 
Vision and a Strategy (NRC, 2007; Bhattacharya et al., 2011). The NRC proposed a 
transition from in vivo low-throughput animal toxicity testing to an in vitro high-
throughput approach utilizing well-designed mechanistic information-based assays. This 
in vitro approach would take advantage of early cellular perturbations post-exposure 
associated with toxicity endpoints in human cell lines and tissues to elucidate mechanistic 
information regarding the mode(s) of action for a potential xenobiotic or mixture (Attene-
Ramos et al., 2013). Additionally, the high-throughput nature of this approach would 
allow for testing on a wide range of doses, especially low doses, which is not currently 
possible with traditional whole animal studies (Bhattacharya et al., 2011). New risk 
assessment approaches would include a suite of assays in order to cast a wide net on early 
cellular changes, such as changes in cellular bioenergetics, and various pathway 
perturbations, such as alterations in post-translational modifications post-exposure, to 
fully understand the cellular response, whether that be adaptation after exposure to a new 
homeostatic state, or cell death (Andersen and Krewski, 2009).  
 Recent advances in systems toxicology have opened the door for the collection 
and analysis of large amounts of mechanistic data across a wide dosing range and time 
scale. Incorporating toxicodynamic factors for risk assessment can aid in our 
understanding of xenobiotic toxicity. The term toxicodynamics can be succinctly 
described as what the toxicant does to the body. Toxicodynamic analyses interrogate the 
spatiotemporal interaction of a xenobiotic with biological targets, the corresponding 
disruption of molecular pathways and bioenergetics, and downstream effects after 
exposure (Boelsterli, 2007).  
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 Marrying toxicokinetic and toxicodynamic approaches for risk assessment can 
offer a wealth of knowledge regarding xenobiotic exposure and the biological 
perturbations associated with 
exposure and their corresponding 
effects (Figure 1.2). Perturbations 
of biological processes by 
xenobiotic exposure can elicit 
early cellular changes, leading to 
an adaptive stress response for 
continued survival or adverse 
response leading to toxicity 
(Andersen, 2010).  Early cellular 
changes corresponding to 
toxicodynamics will be 
highlighted in this work, 
specifically intracellular signaling perturbations (e.g., post-translational modifications 
after chemical exposure) and alterations in cellular bioenergetics. 
 
1.2.1 Intracellular signaling perturbations associated with exposure 
 The toxicodynamic components of early cellular changes, biological 
perturbations, and corresponding response yield valuable mechanistic information for 
toxicity risk assessment. Early and late effects associated with chemical exposure are 
Figure 1.2. Early cellular changes related to biological 
outcome. Toxicokinetic components of exposure involve 
the absorption of the chemical exposure, biotransformation, 
and distribution resulting in the tissue dose. The chemical 
then interacts with molecular targets, perturbing 
endogenous pathways and processes, resulting in early 
cellular changes, which contributes to the toxicodynamic 
response post-exposure. Early cellular changes can lead to 
adverse effects (toxicity) or adaptive response and survival. 
Adapted from Andersen et al. (2005). Reprinted with 
permission from Elsevier. 
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mediated by plasma membrane receptor proteins acting as a sensor and their downstream 
signaling pathways (Bhattacharya et al., 2011). Signaling pathways are not static linear 
pathways that simply transmit signals, but are responsible for encoding and integrating 
both internal and external cues (Kholodenko, 2006). Exposure to chemical insults can 
perturb the dynamic and highly coordinated signaling pathways responsible for normal 
biological function and maintenance (Houck and Kavlock, 2008). Additionally, chemical 
insult at one molecular target and pathway can propagate throughout the signaling 
network due to pathway crosstalk and the interconnectivity of various signaling cascades 
(Kholodenko et al., 2010). As such, cellular spatiotemporal signaling dynamics are 
responsible for integrating and interpreting intra- and extracellular cues to make cellular 
fate decisions, such as proliferation, differentiation, or programmed cell death (apoptosis) 
(Murphy et al., 2004; von Kriegsheim et al., 2009; Kholodenko et al., 2010). 
 Signaling networks are primarily regulated by post-translational modifications 
(PTMs). PTMs are vital to signaling coordination and diversification of proteins for 
various functions (Wold, 1981; Aye-Han et al., 2009). PTMs can modify proteins after 
translation via complex molecules (glycosylation and isoprenylation), peptides or 
proteins (ubiquitylation and sumoylation), chemical groups (acetylation, methylation, and 
phosphorylation), and cleavage (proteolysis) (Wang et al., 2014). The rapid 
toxicodynamic response of cells to xenobiotics is primarily coordinated by signal 
transduction networks, which follow a simple framework: the phosphorylation / 
dephosphorylation cycle mediated by kinases and phosphatases (Kumar et al., 2007; 
Schilling et al., 2009). Kinases are intimately involved in the regulation of signaling 
events relevant to cellular death and survival processes (Bononi et al., 2011). Xenobiotics 
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can interfere with kinase signaling via activation (e.g., overstimulation) or inhibition 
(Boelsterli, 2007). Kinases can be activated/deactivated via the addition or removal of a 
phosphate group at serine, threonine, and tyrosine residues (-OH containing amino acids) 
(Wold, 1981), shown in Figure 1.3.  
 
The phosphorylation/dephosphorylation of a protein acts as a molecular switch to 
activate or deactivate a protein. In the catalytic domain of protein kinases, the -OH group 
on serine, threonine, and tyrosine residues act as a nucleophile, attacking the γ-phosphate 
on adenosine triphosphate (ATP) resulting in the transfer of a phosphoryl group to the 
protein (Endicott et al., 2012). In this scheme, magnesium is a critical component for 
protein phosphorylation, acting as a supportive chelator. The covalent bonding between 
phosphate groups and protein kinases typically induce a conformational change, aiding or 
preventing protein-protein (enzyme-substrate) interactions (Wang et al., 2012). It is this 
Figure 1.3. Mechanism of phosphorylation. This reaction scheme 
uses serine as the example residue, however, this mechanism is true 
for tyrosine and threonine phosphorylation as well.  
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protein-protein/enzyme-substrate interaction where critical cellular information can be 
transmitted throughout the signaling network.  
 Under xenobiotic stress conditions, many pathways can be perturbed, including 
survival and death pathways. The three major stress-activated pathways are the mitogen-
activated protein kinase (MAPK) pathway (also commonly referred to as extracellular 
signal-regulated kinases (ERK) pathway), the stress-activated protein kinase (SAPK) 
pathway (also commonly referred to as jun N-terminal kinase (JNK) pathway), and the 
p38 pathway (Paul et al., 1997; Tibbles and Woodgett, 1999; Pouyssegur et al., 2002). 
These stress pathways are endogenously active, controlling cellular fate via 
transcriptional activation and/or inhibition of genes regulating survival/proliferation and 
cell death (Boelsterli, 2007). These pathways were traditionally thought of as discrete 
linear signaling cascades; however, it is now well known that they are merely 
components of a dynamic and highly interconnected network of pathways that contain 
many crosstalk, feedback and feedforward mechanisms to adequately and efficiently 
response to stress-inducing stimuli (Junttila et al., 2008; Kholodenko et al., 2010). 
Therefore, it is the delicate balance/imbalance of these pathways that decides the cell's 
ultimate fate (Bononi et al., 2011; Currie et al., 2014). The highly dynamic and 
interconnected nature of signaling networks has made it increasingly difficult to elucidate 
and predict network responses to xenobiotic stress. However, advances in computational 
and network biology, high-throughput experimental techniques, such as -omics 
investigations using mass spectrometry, multiplex bead-based ELISA (enzyme-linked 
immunosorbent assay) suspension array systems, and microchip arrays, and public 
databases have greatly improved signaling research. With these advances, new 
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toxicological risk assessment approaches for determining potential toxic outcome of a 
xenobiotic or mixture using mechanistic information can be attempted, as postulated by 
the NRC report (NRC, 2007).         
  
1.2.2 Bioenergetic changes post-exposure 
 Kinase signaling is an energy demanding process, and its reliance on 
phosphorylation results in the consumption of substantial amounts of available adenosine 
triphosphate (ATP) (Hammerman et al., 2004). ATP-production governs ATP-consuming 
processes, such as signal transduction in mammalian cells, and this production is 
primarily driven by oxidative phosphorylation within mitochondria (Buttgereit and 
Brand, 1995; Ainscow and Brand, 1999). Mitochondria are the energy production hub of 
a cell via production of ATP via phosphorylation and, of equal importance, key mediators 
in kinase signal transduction, regulating cell survival, proliferation, differentiation, and 
death (Hammerman et al., 2004; Mohamed et al., 2014). Due to their critical role in many 
cellular processes, mitochondria are also susceptible to xenobiotic exposure effects. 
Additionally, irreversible processes leading to cell death primarily rely on two 
mitochondria-related phenomena: 1) the inability to reverse mitochondrial dysfunction, 
resulting in ATP depletion and 2) the disturbance of membrane function (both 
mitochondrial membrane and plasma membrane) (Law and Elmore, 2008). Therefore, 
maintenance of mitochondrial bioenergetics and integrity is critical to cellular fate.    
Mitochondria are comprised of several key features: the outer mitochondrial 
membrane, intermembrane space, inner mitochondrial membrane, and matrix (Figure 
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1.4). The outer mitochondrial membrane is permeable to small molecules (molecular 
weight < 5,000 g/mol) and ions, which readily diffuse through transmembrane porin 
proteins, such as voltage-gated anion channel (VDAC) (Ninomiya-Tsuji, 2008). The 
inner membrane, however, is impermeable to most molecules and ions, including protons 
and ATP (Lehninger et al., 2008). The inner membrane contains the proteins that make 
up the electron transport chain (ETC). Additionally, the inner membrane contains 
numerous transport proteins to allow metabolites to pass through into the matrix and to 
export ATP generated by the electron transport chain (ETC) into the intermembrane 
space (Ninomiya-Tsuji, 2008). The space between the two membranes is called the 
intermembrane space. The intermembrane contains a small heme-containing protein 
called cytochrome c within the intermembrane-side of inner membrane folds (referred to 
as intracristae space), which acts as an electron carrier for Complex III on the ETC, and 
when released from the outer membrane, can initiate caspase-dependent apoptosis 
Figure 1.4. Mitochondria. The two membranes of mitochondria are shown above as the outer 
membrane (OM) and inner membrane (IM). The VDAC transmembrane protein is shown in yellow at 
the OM and ANT transmembrane protein is in teal at the IM to illustrate the shuttle of ATP from ATP 
synthase (also known as Complex V) of the ETC to the cytosol. Small blue dots indicate cytochrome c 
within the intermembrane space and roman numeral cartoons indicate ETC subunits. Adapted from 
Desagher and Martinou (2000), reprinted with permission from Elsevier. 
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(Desagher and Martinou, 2000; Kroemer et al., 2007). The protein adenine nucleotide 
translocase (ANT) is the transporter responsible for shuttling ATP from the matrix to the 
intermembrane space (Ninomiya-Tsuji, 2008). Additionally, ANT forms a complex with 
VDAC (an outer mitochondrial membrane transporter), commonly referred to as the 
permeability transition pore (PTP) that can compromise the impermeability of the 
mitochondrial membranes.  If the PTP is open, an influx of ions and water can bombard 
the matrix, causing swelling, loss of membrane potential, and uncoupling of oxidative 
phosphorylation, eventually leading to cell death (Fosslien, 2001). Finally, the matrix, 
which is in the space contained by the inner membrane, houses all energy-yielding 
oxidative reactions, such as the citric acid cycle, fatty acid oxidation, and the ETC 
(Ninomiya-Tsuji, 2008). The matrix also contains important ions (magnesium, calcium, 
and potassium), metabolic intermediates, ATP/ADP, and mitochondrial DNA. 
Mitochondrial DNA genes are transcribed and translated within the matrix as well.     
The number of mitochondria in each eukaryotic cell can vary depending upon the 
cell type. Red blood cells (erythrocytes) do not have mitochondria, however, the heart, 
kidney, and liver are considered mitochondria-rich (Veltri et al., 1990). Mitochondria-
rich cell types are especially sensitive to xenobiotics that target the ETC. There are two 
classes of ETC inhibitors: 1) xenobiotics that block the transport of electrons via binding 
to ETC enzyme complexes (e.g., deguelin binding to Complex I) and 2) xenobiotics that 
stimulate the flow of electrons at one portion of the ETC, but shunt electrons away from 
their normal route by acting as an electron acceptor. Disruption of normal ETC function 
and mitochondrial bioenergetics can have deleterious effects (both acute and chronic) on 
the target tissue as well as whole organism. Examples of pathological conditions where 
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mitochondrial dysfunction plays a critical role are neurodegenerative diseases, 
neurotoxicity, heart disease (myocardial infarction and atherosclerosis), liver injury 
(ischemic injury and cholestasis), obesity, and cancer (Kroemer et al., 2007; Nunnari and 
Suomalainen, 2012). Thus, mitochondrial bioenergetics should be carefully considered 
and included in toxicity risk assessment. 
 
1.2.3 Timescale of exposure effects 
 The toxicity of a xenobiotic or mixture at their intended molecular/tissue target(s) 
can vary over exposure time and any change is commonly known as time-dependent 
toxicity (Dawson et al., 2014). The initial toxicodynamic response to any xenobiotic or 
mixture exposure is predominantly coordinated by signal transduction networks, which 
can initiate response within the first few seconds to minutes of exposure. The time course 
from initial toxicodynamic response(s) to cell death following exposure can have a vast 
range (Rehm et al., 2009). For example, the time delay between xenobiotic exposure and 
execution of apoptosis can take from several hours to over a day (Lemasters et al., 1998; 
Messam and Pittman, 1998). With this in mind, monitoring early cellular changes that 
contribute to adaptive stress response (survival and new homeostatic state) or lead to 
adverse effects (apoptosis, carcinogenicity) may aid toxicological understanding and 
ultimately the prediction of potential adverse effects from xenobiotic or mixture 
exposures.  
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1.3 Experimentally testing early cellular changes that may contribute to exposure 
sensing and response 
Traditional risk assessment testing techniques involve screening potential agents 
using in vivo and in vitro endpoint experiments, such as neurotoxicity or developmental 
toxicity, and mode of action analysis, such as cytotoxicity or mutagenicity (Dix et al., 
2007). However, the recent paradigm shift charged by the NRC report has initiated a new 
chemical risk assessment approach that utilizes high-throughput in vitro screening assays 
to exploit early cellular changes (such as signaling pathway perturbations and alterations 
in cellular bioenergetics) to reveal mechanistic information about adverse or adaptive 
effects after xenobiotic exposure. 
 
1.3.1 In vitro cell culture 
The large number of potential toxic chemical agents that have yet to be fully 
characterized pose a significant problem for risk assessment testing (NRC, 2007). 
Traditional in vivo methods cannot be solely relied on for risk assessment testing due to 
the low-throughput, high financial and time cost, and the sheer number of animals 
necessary to test the thousands of chemicals yet to be evaluated. Further, the utility of 
mechanistic information from animal studies has been questionable due to disappointing 
cross-species extrapolation for real life low dose human exposure effects (Houck and 
Kavlock, 2008).  Thus, a paradigm shift from traditional in vivo methods to an in vitro 
approach utilizing assays to collect mechanistic information for pathway/network 
analyses and eventual prediction modeling with computational toxicology has been 
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initiated by the NRC report (NRC, 2007). The NRC suggested human in vitro high-
throughput screening assays to measure early cellular effects, such as perturbations of 
critical signaling pathways related to survival and death (referred to as potential adverse 
outcome pathways by the NRC), across a wide dosing range and multiple cell lines, both 
immortalized and primary cell culture (Andersen et al., 2010).  
The paradigm shift from traditional in vivo animal studies to new in vitro high-
throughput screening assays using human cell lines raises some new questions. What cell 
type should be used (immortalized vs primary)? Primary cell culture is culture that is 
initiated immediately following tissue extraction from the sample organism. Once the 
cells reach confluency (typically 80 % of the culture-containing flask covered by cells, 
without overlapping each other), cells need to be subcultured (also known as passaging) 
by dividing the cells into multiple culture flasks for continued growth. Primary cell 
culture can typically only be subcultured several times before they can no longer be used. 
On the other hand, immortalized (continuous) culture is when cells are cultured for a 
theoretically infinite number of subcultures, which is achieved via transformation 
(spontaneously transformed via cancerous cell lines or chemically induced 
immortalization). Immortalized/continuous cell lines offer a low cost, reproducible in 
vitro experimental set-up, but may result in disparate responses than those achieved in 
primary culture or in vivo due to their continuous cell cycle progression. Even though the 
response may be slightly different from immortalized to primary or in vivo studies, useful 
mechanistic information can be collected for toxicity risk assessment. Fortunately, there 
are several cell lines commercially available that have libraries of data, such as HepG2 
(human hepatocellular carcinoma) for liver toxicity (O'Brien et al., 2006), MCF-7 
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(human breast cancer) for estrogen responsive toxicity studies (Holliday and Speirs, 
2011), and HEK293 (human embryonic kidney cells) for kidney toxicity (Sasaki et al., 
2007).  
Liver injury and toxicity due to xenobiotic exposure is a major concern for 
pharmaceutical regulatory and toxicological risk assessment (Kavlock et al., 2012). 
Additionally, the liver plays a vital role in xenobiotic biotransformation after exposure 
(Mersch-Sundermann et al., 2004). Thus, in vitro high-throughput approaches using 
human-derived liver cell lines to probe important early cellular exposure effects and 
potential pathway perturbations are necessary for toxicological risk assessment. The U.S. 
EPA ToxCast research program was initiated to screen previously untested environmental 
chemicals for adverse effects using a large number of high-throughput bioassays. Data 
collected from ToxCast assays is made available through the ToxCast data library to 
disseminate chemical exposure profiles to further toxicology research and gain a 
mechanistic understanding of chemical exposure (Sipes et al., 2013). The ToxCast library 
has two liver models for toxicity testing: primary rat hepatocytes and HepG2 cells 
(Kavlock et al., 2012). Both models offer important information about hepatotoxicity. 
Due to the limited availability of human primary liver cells, rat primary hepatocytes are 
often used for hepatotoxicity risk assessments. Previous studies have shown that 
xenobiotic metabolizing enzymes have significant interspecies variation (Selkirk, 1977; 
Maslansky and Williams, 1982). An accepted alternative to primary rat hepatocytes for 
liver toxicity research is the HepG2 cell line. A benefit of using HepG2 vs primary rat 
hepatocytes is that they are human-derived. Most importantly, the HepG2 cell line retains 
endogenous xenobiotic metabolizing enzymes, whereas primary hepatocyte culture 
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typically loses these vital enzymes (Knasmuller et al., 1998).  The in vitro studies 
discussed in Chapters 2 - 4 use the HepG2 cell line as the model system for several 
xenobiotic exposure proof-of-principle approaches.  
 
1.3.2 Real time in vitro assays to measure early cellular changes 
 As discussed previously, initial cellular responses to xenobiotic exposure are 
rapid, dynamic, and highly integrated for determining eventual cellular fate. Assays 
capable of capturing these dynamic processes and relating them to apical outcomes (cell 
death, survival, plasma membrane degradation) are necessary for xenobiotic risk 
assessment predictions. The real-time assays used in this dissertation are related to 
mitochondrial bioenergetics (reduced form of nicotinamide adenine dinucleotide 
(NADH) production, cellular oxygen consumption, and estimations of ATP from NADH 
and oxygen consumption) and cell death (plasma membrane degradation).  
  
1.3.2.1 Mitochondrial bioenergetics assays: NADH generation and oxygen consumption 
 NADH is a vital component of mitochondrial function, energy metabolism and 
oxidative stress (Ying, 2008). As a critical component of the ETC and bioenergetics, 
early cellular effects and perturbations can be monitored via changes in cellular NADH. 
One of the most useful and remarkable features of NADH is that it strongly absorbs at 
340 nm; therefore, real time kinetic measurements of cellular NADH can be obtained 
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without the assistance of any fluorescent tag or probe (McComb et al., 1976; Vrana et al., 
2014).  
 Intracellular molecular oxygen is a key component of cellular homeostasis and 
mitochondrial oxidative phosphorylation via the ETC. After xenobiotic exposure, early 
cellular changes associated with mitochondrial bioenergetics and cellular respiration can 
be monitored using real-time oxygen consumption assays. Determining key time points 
related to perturbations in cellular respiration can further the mechanistic understanding 
of xenobiotic exposure and eventual cell survival/death. High-throughput real-time assays 
for oxygen consumption that do not perturb endogenous intracellular activity are limited. 
The most popular method for cellular oxygen consumption is the Clark electrode, 
however it is a very low-throughput method (one sample at a time) (Diepart et al., 2010). 
The development of oxygen sensitive extracellular probes that can reproducibly measure 
discrete changes in oxygen consumption over time (with comparable sensitivity to the 
Clark electrode) have significantly advanced mitochondrial and toxicological research. 
Once such probe was developed by Luxcel Corp (Cork, Ireland), manufactured as 
MitoXpress. The MitoXpress probe is an extracellular phosphorescent platinum-
coproporphyrin dye with a long emission time and stable phosphorescent signal that can 
be used for 24 hour kinetic measurements in a 96-well plate format, making it high-
throughput (Dmitriev et al., 2010). For this assay, the MitoXpress probe is quenched by 
molecular oxygen (O2). A decrease in extracellular O2 concentration (increase in cellular 
oxygen consumption) is measured as an increase in signal (less probe is quenched by O2), 
whereas an increase in extracellular O2  concentration is measured as a decrease in signal 
(more O2 to quench the probe; less oxygen is consumed by the cell) (Diepart et al., 2010).   
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 Finally, one of the most critical components of bioenergetics, ATP can be 
measured to monitor cellular perturbations after xenobiotic exposure. Previously, assays 
for intracellular ATP have employed fluorescent tags, which can potentially disrupt 
endogenous intracellular activity (e.g., FRET) (Berg et al., 2009), or involve cell lysis 
(e.g., luciferase assay), making real-time in vitro ATP measurements not possible 
(Imamura et al., 2009). Monitoring relative ATP generation in response to chemical 
insult without potentially disrupting sensitive intracellular activity is imperative. To this 
end, the Boyd Lab has developed an extracellular approach to estimate ATP production 
with data collected from real-time oxygen consumption and NADH production assays. 
These data sets allow for stoichiometric determinations of ATP production in real-time. 
Theoretically, mitochondrial oxidative phosphorylation is responsible for producing a 
substantial portion of cellular ATP, and traditionally, NADH and oxygen are related to 
ATP production as shown below (Kadenbach, 1986; Lehninger et al., 2008): 
)1(3
2
1
1 2 ATPONADH   
Since our MitoXpress assay monitors oxygen consumption, the equation can be doubled: 
)2(62 2 ATPONADH   
Additionally, cells can produce ATP via glycolysis, where 1 ATP is generated for each 
available NADH.  This may be particularly true for HepG2 cells, since many cancer cells 
have been shown to have a high reliance on glycolysis due to the Warburg effect 
(Warburg, 1956; Vander Heiden et al., 2009). To account for ATP production when there 
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is limited or no oxygen, an “if then else loop” was used to calculate theoretical ATP 
generation: 
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This method has proven successful for two disparate xenobiotics, demonstrating a strong 
correlation to relative ATP measurements collected via the luciferase assay (Vrana et al., 
2014). 
 
1.3.2.2 Plasma membrane degradation 
 The "point-of-no-return" for which a cell decides to die has yet to be determined 
(Kroemer et al., 2005). However, certain cellular features implicate a cell has died; one 
such feature is the loss of plasma membrane integrity (Kroemer et al., 2005). A simple, 
reproducible, and high-throughput assay for plasma membrane degradation is the 
ethidium homodimer-1 (EthD-1) assay, commonly referred to as a "dead assay." The 
EthD-1 dye is impermeable for cells with an intact plasma membrane. However, when 
the plasma membrane is permeabilized, the EthD-1 can penetrate the cell and intercalate 
with DNA nucleic acids. When EthD-1 is bound to strands/segments of DNA, the dye 
emits a strong red fluorescence, whereas in the absence of available DNA segments, the 
dye has a very low intensity fluorescent signal (Grogan et al., 2002). This dye is not only 
useful for in vitro plate reader-based assays, but also fluorescence microscopy.  
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1.3.3 Endpoint in vitro assays to measure early cellular changes and long term exposure 
effects 
 The previous assays described are best suited for in vitro, real-time kinetic 
measurements using a high-throughput platform, such as 96+ well plate assays. However, 
assays that require cell lysis or disruption of cellular function are commonly referred to as 
endpoint assays. The high-throughput in vitro endpoint assays used in this work are MTT 
(cell viability), luciferin/luciferase (intracellular ATP), and multiplex bead-based ELISA 
(phosphoprotein or cytokine).   
 
1.3.3.1 Viability  
 There are several viability measurements used for in vitro experiments that are 
cheap, easy to use, and high-throughput. Examples include the lactate dehydrogenase 
(LDH) assay, neutral red, and methyl tetrazolium (MTT) assay. There are benefits and 
drawbacks for each method, however, of the three, neutral red and MTT are the most 
sensitive for cell viability (Fotakis and Timbrell, 2006). While all three assays are used to 
determine viability, most are used as an orthogonal measurement of cytotoxicity (i.e., not 
used alone), or for initial screening of appropriate dosing ranges (Galluzzi et al., 2009). 
The only true assays for cell death measure plasma membrane degradation, such as the 
EthD-1 dye. However, due to its low cost, robustness, and ease of use, MTT is commonly 
included in studies to estimate viability. The MTT reagent, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide, is a yellow water soluble salt that is converted into 
insoluble formazan crystals in the presence of succinate dehydrogenase within the 
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mitochondria of metabolically active cells via cleavage of the tetrazolium ring (Fotakis 
and Timbrell, 2006). The insoluble purple formazan crystals can be solubilized by DMSO 
or detergent for quantification via absorbance using 96-well plate spectrophotometry.    
 
1.3.3.2 Intracellular ATP  
 As described previously, ATP is a critical biomolecule for cell survival. While 
real-time assays for ATP generation are limited, endpoint assays for ATP are widely used 
and extremely sensitive (Imamura et al., 2009). Additionally, ADP:ATP ratios have been 
used to measure cell viability, apoptosis, and necrosis (Bradbury et al., 2000). The 
predominant endpoint ATP assay is the D-luciferin-luciferase assay, which requires cell 
lysis for in vitro applications. The luciferase assay is a bioluminescent assay where the 
substrate D-luciferin is converted into oxyluciferin, by the luciferase enzyme in the 
presence of ATP. The conversion from luciferin to oxyluciferin emits a stable, relatively 
long-lived light emission (~30 minutes). This assay is very sensitive, ranging from 10
-13
 
mol to > 10
-6
 mol ATP, and can be used for a wide variety of sample matrices, such as 
soil, milk, plasma, and cell culture (Kricka, 1988). 
 
1.3.3.3 Multiplex bead-based suspension array   
The analysis of key signal transduction perturbations via PTM assays is one of the 
most valuable tools for intracellular exposure mechanism-based risk assessment.  Upon 
insult by a xenobiotic, the cellular toxicodynamic response is coordinated by signal 
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transduction networks, which follow a rudimentary framework, the phosphorylation / 
dephosphorylation cycle mediated by kinases and phosphatases (Kumar et al., 2007; 
Schilling et al., 2009). Traditionally, western blot and immunoprecipitation have been the 
assays of choice for phosphoprotein analyses (Schmelzle and White, 2006). While 
western blotting has been the gold standard for phosphoprotein determinations, it is very 
low throughput. A multiplexed and high-throughput assay for phosphoprotein analysis to 
elucidate network perturbations and mechanistic exposure information is the bead-based 
(microsphere) sandwich-based ELISA, developed by Luminex (Poetz et al., 2010). This 
assay is a modification of a traditional ELISA, whereby the capture antibody (Ab) is 
immobilized to magnetic (or non-magnetic) polystyrene microspheres (Figure 1.5).  
 
 
Figure 1.5. Bead-based ELISA. A microsphere, which can be magnetic or non-magnetic, (shown in 
red) has two fluorescent dyes  (excited by the same wavelength of light but emit different 
wavelengths) encapsulated within the bead. These dyes act as the bead recognition element, and the 
ratio of dyes identifies the bead type (e.g., bead region 1 has a ratio of 1:100 for the two dyes, and this 
region has the Ab for ERK protein immobilized on the surface). The assay proceeds as a traditional 
sandwich ELISA (with the exception that the capture Ab is immobilized to a microsphere) where the 
capture Ab is specific for one of your desired analytes (e.g, anti-ERK Ab is selective for ERK 
protein) and the biotinylated detection Ab recognizes a separate epitope of your desired analyte (e.g., 
anti-phosphoERK Ab to recognize phosphorylated ERK). The biotinylated detection Ab then binds 
with the fluorescent reporter, streptavidin-phycoerythrin (due to the extremely high binding affinity of 
biotin for streptavidin). Antibody, Ab; phycoerythrin (PE).  
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The assay workflow proceeds as follows: 1) capture Ab beads are added to the 
assay plate wells 2) add the analyte(s)-containing sample and incubate 3) add biotinylated 
detection Ab and incubate 4) add fluorescent reporter (e.g., streptavidin-phycoerythrin 
complex) and incubate 5) analyze samples via suspension array (Houser, 2012).  
Since this is a multiplex method, 100+ different Ab-bead combinations can be 
assayed per well. The beads are coded with two dyes that can be excited by the same 
wavelength but emit different wavelengths. Depending upon the ratio of the two 
encapsulated dyes, the bead region (code) can be measured by the instrument.  In order to 
differentiate between bead dyes and fluorescent reporter dye, the suspension array 
platform utilizes a duel laser system: a red solid state laser (635 nm) to excite dyes 
encapsulated within the microspheres for bead type identification and a Nd:YAG laser 
(532 nm) to excite the phycoerythrin dye (fluorescent reporter). The fluorescent reporter 
is bound to the analyte-bead complex (shown in green, Figure 1.5) for quantitation of the 
captured analyte (Houser, 2012). All emission intensities are detected with a 
photomultiplier tube. This method is high-throughput and requires low sample volume. 
Currently, Luminex-manufactured magnetic microspheres (sold under the name 
MagPlex) have 500 unique bead regions, allowing for 500 different antibody assays to be 
performed per well of a 96-well plate (Luminex, 2015). 
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2. Forecasting cell death dose-response to single chemicals in vitro
1
 
 The rapid pharmacodynamic response of cells to toxic xenobiotics is primarily 
coordinated by signal transduction networks, which follow a simple framework: the 
phosphorylation / dephosphorylation cycle mediated by kinases and phosphatases.  
However, the time course from initial pharmacodynamic response(s) to cell death 
following exposure can have a vast range. Viewing this time lag between early signaling 
events and the ultimate cellular response as an opportunity, we hypothesize that 
monitoring the phosphorylation of proteins related to cell death and survival pathways at 
key, early time-points may be used to forecast a cell's eventual fate, provided that we can 
measure and accurately interpret the protein responses. In this paper, we focused on a 
three-phased approach to forecast cell death after exposure: 1) determine time-points 
relevant to important signaling events (protein phosphorylation) by using estimations of 
ATP production to reflect the relationship between mitochondrial-driven energy 
metabolism and kinase response, 2) experimentally determine phosphorylation values for 
proteins related to cell death and/or survival pathways at these significant time-points, 
and 3) use cluster analysis to predict the dose-response relationship between cellular 
exposure to a xenobiotic and plasma membrane degradation at 24 hours post-exposure. 
To test this approach, we exposed HepG2 cells to two disparate treatments: a GSK-3β 
inhibitor and a MEK inhibitor. After using our three-phased approach, we were able to 
accurately forecast the 24 hour HepG2 plasma membrane degradation dose-response 
                                                 
1
 Parts of this chapter have been published previously, either in part or in full, from Vrana, J.A., Currie, 
H.N., Han, A.A., Boyd, J. (2014) Forecasting cell death dose-response from early signal transduction 
responses in vitro. Toxicol Sci. 140, 338-351. Reproduced with permission from Oxford University Press.  
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from protein phosphorylation values as early as 20 minutes post-MEK inhibitor exposure 
and 40 minutes post-GSK-3β exposure. 
 
2.1 Introduction 
 In mammalian systems, the cellular response to toxic xenobiotics involves the 
complex, yet coordinated transmission of intracellular signaling molecules to determine a 
cell's eventual fate (i.e., survival or death) (Kumar et al., 2007; Schilling et al., 2009). 
The initial pharmacodynamic response to any xenobiotic exposure is predominantly 
coordinated by signal transduction networks, which can initiate response within the first 
few seconds to minutes of exposure. This response follows a simple framework: the 
phosphorylation and dephosphorylation cycle of proteins mediated by kinases and 
phosphatases (Kholodenko, 2006; Newman et al., 2013). However, the time course of 
cell death from exposure to visual morphological changes can have a vast range. For 
example, the time delay between xenobiotic exposure and execution of apoptosis can take 
from several hours to over a day (Lemasters et al., 1998; Messam and Pittman, 1998). 
Based upon the time delay between these early and late responses, we hypothesize that 
monitoring the phosphorylation of proteins related to cell death and survival pathways 
may be predictive of a cell's eventual fate, provided that we can read and correctly 
interpret the protein responses.  
 Considering the vast number of proteins involved in critical intracellular signaling 
processes, the number and type of proteins to be monitored for forecasting a cell's fate 
must be judiciously selected. An advantageous group of proteins to monitor for this 
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approach are kinases involved in the regulation of signaling events relevant to cellular 
death and survival processes.  Irrespective of the cell death modality, the cellular decision 
to survive or die relies on the integration of signals at mitochondrial membranes that 
contribute to mitochondrial membrane permeability (MMP) (Kroemer et al., 2007). By 
monitoring kinases upstream of MMP signaling proteins, a detailed snapshot of the cell's 
own interpretation of exposure can theoretically be determined, and this early signaling 
may foreshadow the cell's fate long before the final steps of cell death occur.      
 Appropriately capturing the time course of critical signaling events that will be 
predictive of cellular survival or death post-exposure is difficult. However, time-points of 
significant deviation may be determined by exploiting the intricate inter-relationship 
between mitochondrial-driven energy metabolism and kinase response in real-time. Most 
importantly, this can be accomplished without potentially disrupting intracellular activity. 
Kinase signaling is an energy demanding process, and its reliance on phosphorylation 
results in the consumption of substantial amounts of available adenosine triphosphate 
(ATP) (Hammerman et al., 2004). ATP-production governs ATP-consuming processes, 
such as signal transduction in mammalian cells, and this production is primarily driven by 
oxidative phosphorylation within mitochondria (Buttgereit and Brand, 1995; Ainscow 
and Brand, 1999). Additionally, it is known that some types of cell death (e.g., apoptosis 
and autophagy) require appreciable amounts of energy due to their reliance on ATP-
dependent processes (Yamamoto et al., 1998; Eguchi et al., 1999; Kanzawa et al., 2004), 
such as activation of caspase signaling cascades (Leist et al., 1997), chromatin 
condensation (Eguchi et al., 1997), and autophagic sequestration (Kondo et al., 2005). 
Therefore, by monitoring energy production processes in the cell in real-time, key time 
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points of significant deviation may indicate critical kinase signaling events relevant to, in 
this study, cell death post-exposure.   
  In this paper, we focused on a three-phased approach to forecast cell death in an 
in vitro system: 1) determine time-points relevant to critical signaling events, 2) 
experimentally determine the phosphorylation of proteins related to cell death and/or 
survival at these significant time-points, and 3) use cluster analysis to predict the 24 hour 
plasma membrane degradation dose-response of cells to xenobiotic exposure. We chose 
the human hepatocellular carcinoma-derived HepG2 cell line as our model in vitro 
system because the liver is rich in mitochondria (Veltri et al., 1990) and this cell line is 
human-derived. Additionally, hepatocellular carcinoma incidence is on the rise in the 
United States with 5-year survival rates of 10% (Altekruse et al., 2009).  To test this 
approach, we chose xenobiotics that have activities at disparate intracellular targets in 
vitro. Specifically, we exposed HepG2 cells to various doses of 4-Benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β (GSK-3β) substrate-
competitive inhibitor (Martinez et al., 2002).  As a therapeutic target, GSK3 has seen a 
recent surge in interest for its multifunctional role in a variety of signaling processes, as 
well as its implication in a number of diseases, such as diabetes, Alzheimer’s, bipolar 
disorder, and cancer (Kim and Kimmel, 2000; Wang et al., 2006). We also exposed 
HepG2 cells to various doses of 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK 
inh II), a MEK1 inhibitor (Bakare et al., 2003). MEK1 has been shown to be 
constitutively active in several carcinoma cell lines, such as hepatocellular carcinoma, 
contributing to cell survival (Ballif and Blenis, 2001; Mitsui et al., 2001). This makes the 
MEK1-MAPK signal transduction pathway an attractive target for chemotherapies 
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(Huynh et al., 2003). By using our three-phased approach, we were able to accurately 
forecast the 24 hour HepG2 plasma membrane degradation dose-response from protein 
phosphorylation values as early as 20 minutes post-MEK inh II exposure and 40 minutes 
post-TDZD-8 exposure.  The implications of this proof of principle study may have a 
broad reaching impact: from the ability to forecast in vitro cytotoxicity of xenobiotic 
exposures to the identification of therapeutic windows for pharmacological treatments. 
 
2.2 Materials and Methods 
2.2.1 Materials     
 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8, cas 327036-89-5), 
Dulbecco's modified Eagle's medium (DMEM), sodium pyruvate, D-glucose, L-
glutamate, and sodium bicarbonate were obtained from Sigma Aldrich (St. Louis, MO). 
2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK inh II, cas 623163-52-0) was 
purchased from CalBiochem (La Jolla, CA, USA). HEPES was purchased from Fisher 
Scientific (USA). Fetal bovine serum, Ethidium homodimer-1 cytotoxicity kit, ATP 
determination kit (luciferase assay), and penicillin-streptomycin were obtained from 
Invitrogen (Carlsbad, CA). HyClone phosphate buffered saline (PBS) was purchased 
from Thermo Scientific (USA). Cell lines and MTT assay kits were obtained from 
American Type Culture Collection (Manassas, VA).  MitoXpress oxygen probe was 
obtained from Luxcel Corporation (Cork, Ireland). Deionized water used in this study 
was prepared with the Milli-Q Water System (Millipore, Bedford, MA).  
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2.2.2 Cell culture   
 Human hepatocellular carcinoma-derived HepG2 cells were cultured in DMEM, 
supplemented with 2 g/L D-glucose, 2 mM L-Glutamate, 5 mM HEPES, 24 mM sodium 
bicarbonate, 1 mM sodium pyruvate, 10% fetal bovine serum, 100 U/mL penicillin, and 
100 mg/mL streptomycin. Cells were maintained in a humidified atmosphere at 37°C, 5% 
CO2 and passaged at 80 % confluence.  
 
2.2.3 Dosimetry   
 For MTT, NADH, cellular ATP, and plasma membrane degradation assays, cells 
were seeded into clear-bottom, 96-well plates (black-sided for fluorescence assays) at a 
concentration of 4 x 10
4
 cells per well in DMEM without phenol red and allowed to grow 
for 24 hours before dosing. For multiplex phosphoprotein assays, cells were seeded in 12-
well plates at a concentration of 5 x 10
5
 cells per well in DMEM without phenol red and 
allowed to grow for 24 hours before dosing. For oxygen consumption assays, cells were 
seeded into clear-bottom, black-sided 96-well plates at a concentration of 8 x 10
4
 cells 
per well in DMEM without phenol red and allowed to grow for 24 hours before dosing.   
Medium was then aspirated from wells and cells were challenged with TDZD-8 or  MEK 
inh II.  TDZD-8 and MEK inh II were prepared so that resulting well concentrations 
would be < 1 % DMSO. 
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2.2.4 MTT assay   
 After 24 hours of exposure to TDZD-8 (10, 20, 30, 40, 50, or 100 µM) or MEK 
inh II (1, 5, 10, 20, 50, or 100 µM), cell viability was determined using the MTT (3-(4,5-
dimethyl)-2,5-diphenyl tetrazolium bromide) assay, according to the manufacturer’s 
protocol. This assay is based on the reduction of tetrazolium MTT to formazan by 
metabolically active cells, in part by the action of dehydrogenase enzymes, to generate 
reducing equivalents such as NADH and NADPH.  Briefly, MTT reagent was added to 
the wells of the microplate, and after four hours of incubation at 37°C, intracellular 
formazan crystals were solubilized with the provided detergent solution.  Absorbance 
values were obtained using the Tecan InfiniteM1000 plate reader (Tecan US, Raleigh, 
NC) with a measurement wavelength of 570 nm and a reference wavelength of 700 nm, 
read from the bottom.  Assay was  performed in quadruplicate.  Relative viability was 
calculated by subtracting the negative control (contained no cells) and normalizing to 
controls, which received dosing vehicle (< 1% DMSO).   
 
2.2.5 Oxygen consumption assay 
 Immediately after dosing with TDZD-8 (10, 20, 30, 40, or 50 µM) or MEK inh II 
(1, 5, 10, 20, or 50 µM), cellular oxygen consumption was assessed using the MitoXpress 
probe, according to manufacturer’s protocol.  Briefly, oxygen-sensitive probe was diluted 
to a stock concentration of 1µM, and stock probe was diluted 1:15 in each well of a black 
walled 96-well plate containing cells (8 x 10
4
 cells/well); 100 µL of pre-warmed mineral 
oil was also added to each well to block ambient oxygen from the cells.  After pre-
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warming the plates at 37°C for 1 hour, cells were challenged with varying doses of 
TDZD-8 or MEK inh II.  Immediately following addition of TDZD-8 or MEK inh II, 
oxygen consumption was determined by measuring fluorescence.  Fluorescent signal was 
obtained using the Infinite M1000 microplate reader (Tecan US, Raleigh NC) with 
excitation wavelength of 380 nm and emission wavelength of 650 nm, reading from the 
bottom every 10 minutes for 24 hours after dosing.  Experiments were performed in 
quadruplicate.  Relative oxygen consumption was calculated by normalizing to controls, 
which received dosing vehicle (< 1% DMSO).   
 
2.2.6 NADH assay   
 Immediately after dosing with TDZD-8 (10, 20, 30, 40, or 50 µM) or MEK inh II 
(1, 5, 10, 20, or 50 µM), NADH generation was determined by measuring absorbance.  
The absorbance of NADH at wavelength 340 nm  was measured every 10 minutes for 24 
hours.  Experiments were performed in quadruplicate.  Relative NADH generation was 
calculated by normalizing to controls, which received dosing vehicle (< 1% DMSO).  
 
2.2.7 Cellular ATP assay  
 The boiling water method was used to extract cellular ATP from attached cells, as 
described previously (Yang et al., 2002). After 40 minutes, 10 hours, or 24 hours of 
exposure to TDZD-8 (10, 20, 30, 40, or 50 µM), medium was aspirated and cells were 
washed twice with PBS. In the same manner, after 20 minutes, 8 hours 20 minutes, or 24 
hours of exposure to MEK inh II (1, 5, 10, 20, or 50 µM), medium was aspirated and 
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cells were washed twice with PBS. Cells were suspended in 100 µL/well boiling 
deionized water with repeated pipetting. The cell suspension was transferred to a 
microcentrifuge tube and centrifuged 12,000 g for 5 minutes at 4°C. Following 
centrifugation, 10 µL of supernatant was used for the ATP luciferase assay, which was 
performed according to the manufacturer's protocol. Bioluminescence was measured 
using the Infinite M1000 microplate reader (Tecan US, Raleigh NC). Experiments were 
performed in quadruplicate. Relative cellular ATP was determined by normalizing to 
positive control, which received dosing vehicle (< 1% DMSO).   
 
2.2.8 Multiplex phosphoprotein assay 
 After 40 minutes or 10 hours of exposure to TDZD-8 (10, 20, 30, 40, 50, or 100 
µM), cells were washed with ice cold PBS and lysed according to manufacturer's 
protocol.  In the same manner, after 20 minutes or 8 hours 20 minutes of exposure to 
MEK inh II (1, 5, 10, 20, 50, or 100 µM), cells were washed with ice cold PBS and lysed 
according to manufacturer's protocol. Total protein concentration was determined using 
the DC Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s 
instructions.  Protein phosphorylation was determined by using the bead-based BioPlex 
suspension array system (Bio-Rad, Hercules, CA) and lysates were prepared according to 
the manufacturer’s protocol.  Beads and detection antibodies against phosphorylated 
AKT (Ser473), ERK1/2(Thr202/Tyr204, Thr185/Tyr187), GSK-3α/β (Ser21/Ser9), 
HSP27 (Ser78), IκBα (Ser32/Ser36), JNK1/2 (Thr 183/Tyr185), MEK1 (Ser217/Ser221), 
p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK (Thr359/Ser363) were obtained 
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from Bio-Rad (Hercules, CA).  Beads and detection antibodies against phosphorylated 
BAD (Ser 112), CREB1 (Ser133), IGFR (Tyr1131), IRS1 (Ser636/Ser639), EGFR (Tyr), 
MSK1(Ser212), p70S6K (Thr421/Ser424), AKT(Thr308), and p53(Ser46) were obtained 
from EMD Millipore.  Relative phosphorylation was calculated by normalizing to 
control, which received dosing vehicle (< 1% DMSO).  TDZD-8 exposed phosphoprotein 
experiments were performed in triplicate and MEK inh II exposed phosphoprotein 
experiments were performed in duplicate.   
 
2.2.9 Plasma membrane degradation assay   
 To determine plasma membrane degradation of HepG2 cells exposed to TDZD-8 
or MEK inh II, the ethidium homodimer-1 (EthD-1) kinetic assay was used.  Twenty-four 
hours after seeding HepG2 cells (4 x 10
4
) in a black-sided clear-bottom 96 well plate, 
culture medium was removed and replaced with probe-containing culture medium (2 µM 
EthD-1).  Dead control wells were exposed to 70% methanol and the plate was incubated 
for 30 minutes.  Following the 30 minute incubation, cells were challenged with TDZD-8 
(10, 20, 30, 40, 50, or 100 µM) or MEK inh II (1, 5, 10, 20, 50, or 100 µM) and read 
immediately after dosing.  Fluorescent signal was obtained using the Infinite M1000 
microplate reader (Tecan US, Raleigh NC) with excitation wavelength of 530 nm and 
emission wavelength of 645 nm, reading from the bottom every 10 minutes for 24 hours 
after dosing.  Experiments were performed in sextuplicate.  Relative plasma membrane 
degradation was determined by normalizing to dead control (received 70% methanol).  
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2.2.10 Statistical Analysis 
 Dose-response curves for MTT assays were generated by best-fit Hill-plot 
regression with varying slope of scatter plot data using Prism V5 (Graphpad Software, 
San Diego, CA).  Selection of time points related to critical signaling events (40 minutes 
and 10 hours for TDZD-8; 20 minutes and 8 hours 20 minutes for MEK inh II) were 
determined by estimating temporal bifurcation points from theoretical ATP generation 
and activity using SAS JMP V12Pro (Cary, NC).  Correlation analysis for theoretical 
ATP generation and relative cellular ATP was determined using SAS JMP V12Pro (Cary, 
NC). Two-way hierarchical cluster analyses with Ward's minimum variance were 
determined by using SAS JMP V12Pro (Cary, NC). Statistical significance for plasma 
membrane degradation (observed and forecasted) was determined by using a two-way 
analysis of variance (ANOVA) with Bonferroni post-test.  A difference of P < 0.05 was 
considered statistically significant.  For viability, plasma membrane degradation 
(observed and predicted), cellular ATP, and relative phosphorylation data, error bars 
reflect standard error of the mean (S.E.M.).   
 
2.2.11 Signaling Pathway Analysis 
 Functional pathway and network analyses were generated with  Ingenuity 
Pathways Analysis (IPA) software (Ingenuity Systems) as described elsewhere (Madoz-
Gurpide et al., 2007). IPA identified pathways from the IPA Library of Canonical 
Pathways that were significant to our phosphorylation data. The 19 proteins used in this 
paper were considered for analysis. For this study, significance between our protein 
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phosphorylation data set (TDZD-8 and MEK inh II) and the molecular and cellular 
function p-score, along with associated network functions, was measured by Fisher’s 
exact test.  The Fisher's exact test calculates a p-value to determine the probability that 
the relationship between the phosphorylated proteins in our data set and a canonical 
pathway, biological function or disease could be related by chance alone. We reported the 
top three biological functions associated with our datasets. 
 
2.3 Results 
2.3.1 HepG2 viability in response to TDZD-8 and MEK inh II 
 For this proof-of-principle study, we first determined the appropriate dosing range 
for TDZD-8, a GSK-3β substrate-competitive inhibitor (IC50 = 2 µM) (Martinez et al., 
2002), and MEK inh II, a MEK1 inhibitor (IC50 = 0.38 µM) (Bakare et al., 2003). 
Previously, MEK inh II has also been shown to inhibit other intracellular targets, such as 
ERK1 (IC50 = 82.9 µM) and Raf1 (IC50 = 34.5 µM) (Bakare et al., 2003).  To accomplish 
this, we measured HepG2 viability via MTT assay in response to varying doses of 
TDZD-8 and MEK inh II at 24 hours post-exposure (Figures 2.1a,b).  From HepG2 
viability, the best-fit Hill-plot regression with varying slope was used to determine the 
EC50 of TDZD-8 (19 ± 1 µM) and MEK inh II (9 ± 1 µM).     
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2.3.2 Estimation of ATP generation to determine critical signaling events   
 Monitoring relative ATP generation in response to chemical insult without 
potentially disrupting sensitive intracellular activity is imperative. To this end, we have 
developed an extracellular approach to determine kinase signaling events on a temporal 
scale by estimating ATP production with data collected from real-time oxygen 
consumption and NADH production assays. These data sets allow for stoichiometric 
determinations of ATP production in real-time. Theoretically, mitochondrial oxidative 
phosphorylation is responsible for producing a substantial portion of cellular ATP, and 
traditionally, NADH and oxygen are related to ATP production as shown below 
(Kadenbach, 1986; Nelson and Cox, 2008): 
)1(3
2
1
1 2 ATPONADH   
Since our assay monitors oxygen consumption, the equation can be doubled: 
Figure 2.1. HepG2 viability to determine relevant TDZD-8 and MEK inh II doses.  HepG2 
viability dose-response curves for a) TDZD-8 and b) MEK inh II. Viability was measured by MTT 
assay and is shown as relative viability. Relative viability was calculated relative to control cells, 
which received dosing vehicle (< 1% DMSO), but no inhibitor. Dose-response curves were generated 
using the best-fit Hill-plot regression with varying slope. The x-axis is shown as log2 to better 
visualize TDZD-8 and MEK inh II dosing range. Error bars reflect ± S.E.M.   
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)2(62 2 ATPONADH   
Additionally, cells can produce ATP via glycolysis, where 1 ATP is generated for each 
available NADH.  This may be particularly true for HepG2 cells, since many cancer cells 
have been shown to have a high reliance on glycolysis due to the Warburg effect 
(Warburg, 1956; Vander Heiden et al., 2009). To account for ATP production when there 
is limited or no oxygen, an “if then else loop” was used to calculate theoretical ATP 
generation: 
4
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To account for variations in ATP generation over time, we calculated the relative ATP 
generation activity (equation 3), which we believe more accurately captures temporal 
bifurcations relevant to critical signaling events. This equation is the average of the 
integrated NADH and O2 consumption assays over time divided by their total NADH 
produced and O2 consumed. We also subtracted the positive control and then added a 
value of one to make generation activity curves relative to control, where a value of 1 on 
the generation activity graph is the same as control.  
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Bifurcation points relevant to critical signaling events are shown in figure 2.2a for 
TDZD-8 (40 minutes and 10 hours) and figure 2.2b for MEK inh II (20 minutes and 8 
hours 20 minutes). Bifurcations were selected by relying on the relative ATP generation 
activity curves, then relating ATP generation activity curve changes to simultaneous 
changes in theoretical ATP generation. The first bifurcation is the point before a 
sustained increase/decrease in ATP generation activity that is simultaneously related to a 
change in theoretical ATP generation curves for 3 or more doses. The second bifurcation 
is selected just after there is a rapid decrease/increase in ATP generation activity that is 
simultaneously related to a change in theoretical ATP generation curves for 3 or more 
doses. To validate our ATP estimation method, we determined cellular ATP at the  
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Figure 2.2. Theoretical ATP generation and activity models indicate key bifurcation points for 
HepG2 cells exposed to  TDZD-8 and MEK inh II.  a) Using the NADH/NADPH absorbance at 340 nm, 
NADH generation was measured every 10 minutes for 24 hours following administration of 10, 20, 30, 40, 
and 50 µM doses of TDZD-8 to HepG2 cells. Data is reported as relative NADH generation, which was 
normalized to controls that received vehicle control (< 1% DMSO). Oxygen consumption of HepG2 cells 
exposed to TDZD-8 was monitored every 10 minutes for 24 hours with an oxygen sensitive probe 
(MitoXpress). An increase in probe signal indicates an increase in oxygen consumption relative to controls, 
which received dosing vehicle (< 1% DMSO).  Theoretical ATP Generation (3rd graph) was calculated 
using the “If then else  loop”, as described in Results, which is based on the stoichiometric production of 
ATP from cellular respiration (oxidative phosphorylation). Relative ATP Generation Activity (4th graph) 
was calculated from Equation 3. Critical signaling events were selected at 40 min and 10 h post-TDZD-8 
exposure from our bifurcation analysis described in Results.  b) HepG2 cells exposed to 1, 5, 10, 20 and 50 
µM doses of MEK inh II were measured and analyzed in the same way as TDZD-8. Critical signaling 
events were selected at 20 min and 8 h 20 min post-MEK inh II exposure from our bifurcation analysis 
described in Results. To determine if the theoretical ATP generation model predicted relative cellular ATP 
levels, the luciferase assay was used to measure cellular ATP at the time-points of interest. Extracted 
cellular ATP of HepG2 cells exposed to either c) TDZD-8 or d) MEK inh II were measured using the 
luciferase assay as described in Materials and Methods. Relative cellular ATP from the luciferase assay of 
TDZD-8 exposed cells (c) was found to be significantly correlated to our theoretical ATP generation (a, 3rd 
graph) for TDZD-8 (r = 0.59, P = 0.021) at the time-points of interest (40 min, 10 h, and 24 h). Relative 
cellular ATP from the luciferase assay of MEK inh II exposed cells (d) was found to be significantly 
correlated to the theoretical ATP generation for MEK inh II (b, 3rd graph) for MEK inh II (r = 0.85, P < 
0.001) at the time-points of interest (20 min, 8 h 20 min, and 24 h). Results were reported as relative to 
controls, which received dosing vehicle (< 1% DMSO) and error bars reflect S.E.M. 
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time-points of interest for each compound using the luciferase assay (Figure 2.2c,d). 
Relative cellular ATP from the luciferase assay was found to be significantly correlated 
to our theoretical ATP generation model for TDZD-8 (r = 0.59, P = 0.021) (Figure 2.2a, 
3rd graph) and MEK inh II (r = 0.85, P < 0.001) (Figure 2.2b, 3rd graph). 
  
2.3.3 Multiplex assay to determine phosphorylation of key proteins 
 After time points of critical signaling events have been identified, a snapshot of 
the pharmacodynamic response to xenobiotic exposure can be determined with a high-
throughput approach. Inclusion of valuable proteins that cast a wide net on cell death or 
survival pathways at these time-points are necessary to capture intracellular processes 
that will determine the cell's eventual fate.  In response to cellular stressors (e.g., 
xenobiotics, endogenous molecules), many kinase pathways converge upon 
mitochondria, which can result in mitochondrial membrane permeabilization (MMP) 
mediated death (Kroemer et al., 2007; Rehm et al., 2009). From this, we chose to narrow 
the list of potential proteins to those that are only a few kinase steps removed from key 
survival or death proteins that are known to alter mitochondrial activity. Specifically, 
mitogen-activated protein kinases (MAPKs) have been the subject of intense research for 
many disease pathologies, especially cancer, due to their role in cell proliferation (Anjum 
and Blenis, 2008).  The EGFR-Ras-Raf-MEK-ERK-RSK signaling network is involved 
in cellular proliferation, survival, differentiation, and motility (Roberts and Der, 2007); 
alterations in the normal function of these proteins has been implicated in cancer and 
other diseases (Sebolt-Leopold and Herrera, 2004).  Dysregulated cAMP response 
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element binding protein (CREB1) has also been implicated in uncontrolled growth and 
survival in several cancer cell lines, making it an excellent candidate for this approach 
(Shukla et al., 2009). JNK and p38 kinases are involved in the coordinated response to 
external stress stimuli, inflammation and apoptosis (for review, see Pearson et al., 2001), 
making them viable candidates for this work. Another class of proteins relevant to cell 
survival and death pathways are heat shock proteins (HSP), specifically HSP27, which 
has been shown to act as a protective protein, binding to cytochrome c, preventing 
apoptosis (Bruey et al., 2000). Two proteins intimately involved in mediating stress 
stimuli signals and cell death are tumor suppressor protein p53 and Akt (Gottlieb et al., 
2002). p53-dependent apoptosis plays a critical role regulating pro- and anti-apoptotic 
factors for transcription, as well as translocating from the cytosol to mitochondria, where 
it interacts with proteins related to MMP (Sorrentino et al., 2013). Akt on the other hand, 
has been shown to phosphorylate BCL-2 family proteins, therefore inhibiting MMP 
(Datta et al., 1997). BAD, another valuable pro-apoptotic BCL-2 family protein, is an 
excellent candidate protein to monitor for this approach due to its intimate relationship 
with MMP-related proteins (Zha et al., 1996). To this end, a multiplex bead-based ELISA 
assay was designed and used to simultaneously determine 19 different protein 
phosphorylation responses for TDZD-8 and 18 different protein phosphorylation 
responses for MEK inh II at time points relevant to critical signaling events from ATP 
production bifurcation points.  Cells were lysed at the pre-selected critical signaling time 
points: 40 minutes and 10 hours post-exposure to TDZD-8 (Figure 2.3) and at 20 minutes 
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Figure 2.4. Protein phosphorylation responses of HepG2 cells to MEK inh II. From the 
previously determined temporal bifurcations (20 minutes and 8 hours 20 minutes), relative protein 
phosphorylation was determined by dosing HepG2 cells with various doses of MEK inh II (1, 5, 10, 
20, 50, and 100 µM) and lysing the cell membrane at a-b) 20 minutes and c-d) 8 hours 20 minutes 
post-exposure.  Relative phosphorylation was calculated by normalizing to controls, which received 
vehicle control (< 1% DMSO). Error bars reflect S.E.M. 
 
Figure 2.3. Protein phosphorylation responses of HepG2 cells to TDZD-8. From the previously 
determined temporal bifurcations (40 minutes and 10 hours), relative protein phosphorylation was 
determined by dosing HepG2 cells with various doses of TDZD-8 (10, 20, 30, 40, 50, and 100 µM) 
and lysing the cell membrane at a-b) 40 minutes and c-d) 10 hours post-exposure.  Relative 
phosphorylation was calculated by normalizing to controls, which received vehicle control (< 1% 
DMSO). Error bars reflect S.E.M. 
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and 8 hours 20 minutes post-exposure to MEK inh II (Figure 2.4); the phosphoprotein 
responses of 19 (or 18) different proteins were determined relative to control, which 
received dosing vehicle (< 1% DMSO).   
 
2.3.4 Hierarchical cluster analysis 
 In order to group protein responses that are relevant to varying doses of TDZD-8 
and MEK inh II, we used the unsupervised (i.e., we did not pre-select clusters) Ward two-
way Hierarchical clustering method (Ward, 1963) (Figure 2.5a-d). Two-way clustering is 
necessary to obtain clusters of protein responses across all doses in the first dimension, 
and dose clusters in the second dimension. Negative control-subtracted raw fluorescence 
values for cells exposed to TDZD-8 (10, 20, 30, 40, 50, or 100 µM) or MEK inh II (1, 5, 
10, 20, 50, or 100 µM), as well as cells exposed to vehicle control only (0 µM), were 
used to determine cluster distances.  By including the 0 µM phosphoprotein response 
values, we can include the distance between no dose and the lowest experimentally 
determined dose to forecast the full plasma membrane degradation dose-response.  
Additionally, if we assume that an arbitrary/infinite dose of a xenobiotic (i.e., TDZD-8 or 
MEK inh II) successfully kills all cells exposed, the fluorescence values due to protein 
phosphorylation should theoretically be zero (via endogenous protein degradation after 
the plasma membrane is compromised). From this basic theoretical assumption, we 
included an "infinite dose" column with raw fluorescence values of zero for each protein 
in the two-way hierarchical cluster analysis.  Importantly, the inclusion of a true 0 µM 
dose and a theoretical infinite dose allows for a full dose-response prediction to be made 
62 
 
without experimentally testing the entire dosing range. As a visual aid, this unsupervised 
hierarchical clustering method yields a heat map of phosphoprotein responses, where blue 
represents low response values and red represents high response values. These clusters 
are based on similarities in phosphoprotein response magnitude profiles. After 
performing two-way hierarchical cluster analysis on each protein for each set of 
replicates (clusters not shown, only averaged responses are depicted in Figures 2.5a-d), 
cluster distances between doses were used for dose-response predictions.   
 
2.3.5 Forecasting dose-response from hierarchical cluster analysis 
 By monitoring the phosphorylation response of proteins involved in cellular 
survival and/or death pathways at early time-points, the fate of the cell may be forecasted.  
After determining the cluster distances from two-way hierarchical cluster analysis with 
Ward's minimum variance, these values were used to forecast the relative plasma 
membrane degradation dose-response of TDZD-8 (Figures 2.5 e,f) and MEK inh II 
exposed HepG2 cells (Figures 2.5 g,h).  To forecast the dose-response, the cluster 
distance between doses including 0 µM (vehicle control) and the theoretical infinite dose 
were organized in order of increasing dose.  These values were then integrated across 
each dose (x) interval and divided by the sum of all dose cluster distances, as described 
by equation 4: 
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Figure 2.5. Forecasting plasma membrane degradation from two-way hierarchical cluster analysis 
distances. The phosphoprotein fluorescence responses of HepG2 cells to various doses of TDZD-8 (10, 20, 
30, 40, 50, and 100 µM) or MEK inh II (1, 5, 10, 20, 50, and 100 µM) were analyzed with the unsupervised 
Ward two-way hierarchical clustering method. Each set of replicates were treated as a different cluster for 
our analyses; however, to save space, we will show the averaged fluorescence values at each time point. 
Shown above, cluster analyss of phosphoprotein responses to: a) TDZD-8 at 20 minutes post-exposure, b) 
TDZD-8 at 10 hours post-exposure, c) MEK inh II at 20 minutes post-exposure, and d) MEK inh II at 8 
hours 20 minutes post-exposure. After the cluster analyses were performed, the cluster distances associated 
with each dose are assembled and integrated across the dosing range to formulate the forecasted relative 
plasma membrane degradation dose-response curve (e-h). E) Experimentally observed relative plasma  
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To determine if the forecasted dose-response (from early time points to TDZD-8 or MEK 
inh II exposure) matched the observed 24 hour plasma membrane dose response, a two-
way ANOVA was performed. The 24 hour observed and forecasted (from 40 minutes 
post-TDZD-8 exposure and 20 minutes and 8 hours 20 minutes post-MEK inh II 
exposure) plasma membrane responses were not significantly different at any dose. The 
24 hour observed and forecasted plasma membrane degradation at 10 hours post-TDZD-8 
exposure were only statistically different at the 10 µM TDZD-8 dose (P < 0.05). 
Additionally, observed vs. forecasted plasma membrane degradation at the early time 
points (20 minutes plasma membrane degradation post-MEK inh II exposure observed vs. 
forecasted and 40 minutes plasma membrane degradation post-TDZD-8 exposure 
observed vs. forecasted) were significantly different (P < 0.05) from each other at 30, 40, 
50 and 100 µM TDZD-8 and 10, 20, 50, and 100 µM MEK inh II indicating that we are 
membrane responses to TDZD-8 at 40 minutes and 24 hours post-exposure are connected with red and 
black solid lines, respectively. The forecasted 24 hour plasma membrane degradation responses that were 
calculated with cluster distances from 40 minutes post-TDZD-8 exposure phosphoprotein responses are 
connected with a red dashed line. F) Experimentally observed relative plasma membrane degradation 
responses to TDZD-8 at 10 hours and 24 hours post-exposure are connected with blue and black solid lines, 
respectively. The forecasted 24 hour plasma membrane degradation responses that were calculated with 
cluster distances from 10 hours post-TDZD-8 exposure phosphoprotein responses are connected with a blue 
dashed line. G) Experimentally observed relative plasma membrane degradation responses to MEK inh II at 
20 minutes and 24 hours post-exposure are connected with red and black solid lines, respectively. The 
forecasted 24 hour plasma membrane degradation responses that were calculated with cluster distances from 
20 minutes post-MEK inh II exposure phosphoprotein responses are connected with a red dashed line. H) 
Experimentally observed relative plasma membrane degradation responses to MEK inh II at 8 hours 20 
minutes and 24 hours post-exposure are connected with blue and black solid lines, respectively. The 
forecasted 24 hour plasma membrane degradation responses that were calculated with cluster distances from 
8 hours 20 minutes post-exposure phosphoprotein responses are connected with a blue dashed line. For 
graphs in figures e-h, relative plasma membrane responses were analyzed using two-way ANOVA. Cluster-
forecasted responses found to be significantly different (P < 0.05) from observed 24 hour responses are 
marked with ^, cluster-forecasted responses found to be significantly different (P < 0.05) from early time-
point observed responses are marked with #, and observed early time-point responses found to be 
significantly different (P < 0.05) from observed 24 hour responses are marked with *. Error bars reflect ± 
S.E.M. 
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not measuring plasma membrane degradation at those early time points, rather we are 
capturing early critical signaling events related to the eventual cellular fate.   
 
2.4 Discussion 
 Understanding the cell's own pharmacodynamic interpretation of exposure to a 
potentially toxic xenobiotic or therapeutic is imperative to determining the eventual 
cellular fate. Before morphological changes (e.g., plasma membrane degradation) 
indicate the overall cellular state, the intracellular domain is coordinating a dynamic and 
networked response that dictates the eventual cellular outcome. By exploiting critical 
pharmacodynamic events related to the eventual cellular fate decision, the cellular 
response to external stimuli (e.g., xenobiotic exposure or general stress) can be forecasted 
from significantly early time points post-exposure.   In this paper, human hepatocellular 
carcinoma derived HepG2 cells were exposed to two disparate inhibitors, TDZD-8 (GSK-
3β substrate-competitive inhibitor) and MEK inh II (MEK1 inhibitor), to test an approach 
that combines several datasets to forecast the eventual cellular outcome. The datasets 
used in this work incorporated theoretical ATP generation for the identification of critical 
signaling bifurcation points, followed by determinations of the phosphoprotein response 
at these time-points post-exposure for further cluster analyses to forecast the plasma 
membrane degradation dose-response at 24 hours of exposure. This concept has a 
universal approach: utilizing the cell's own early responses post-exposure to forecast the 
cell's eventual fate that may be irrespective of the xenobiotic's intracellular mode(s) of 
action.   
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 To our knowledge, reliable in vitro approaches that are capable of determining 
important intracellular processes in real-time, such as ATP production, without 
perturbing native intracellular biochemical processes have yet to be determined (Imamura 
et al., 2009). Real-time oxygen consumption has been used to identify temporal events 
post-xenobiotic exposure that are related to intracellular signaling, due to the relationship 
between oxygen consumption and oxidative phosphorylation (Janssen-Heininger et al., 
2008). While we have had some success using oxygen consumption alone to select 
critical signaling events (Boyd et al., 2013), this method can be improved by exploiting 
the intricate intracellular relationship between NADH generation, oxygen consumption, 
and ATP production.  By extracellularly monitoring analogs of ATP production over time 
after xenobiotic exposure, critical signaling events may be estimated without potentially 
disrupting intracellular activity. In this manner, two bifurcation time points were 
identified for HepG2 cells post-TDZD-8 or MEK inh II exposure. Since kinase signaling, 
which utilizes appreciable amounts of available ATP, is an energy demanding process 
(Hammerman et al., 2004), these early bifurcation points may be indicative of critical 
signaling processes relevant to intracellular-level decision making for the cell's overall 
eventual fate. This approach assumes that all oxygen consumption and NADH generation 
measured in vitro is attributed to oxidative phosphorylation for ATP synthesis. Thus, this 
model does not incorporate oxidative phosphorylation-independent oxygen consumption, 
which can vary based on cell type (Herst and Berridge, 2007; Trimarchi et al., 2000). 
Additionally, cellular glucose, calcium, and magnesium were not measured in this study. 
For future model development, these critical cellular components may be measured to 
more accurately select key time-points. This new approach may translate well into other 
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cell lines with similar amounts of mitochondria, such as heart and kidney (Veltri et al., 
1990), or similar mitochondrial bioenergetics, such as the heart, testes, and brain 
(Menzies and Gold, 1971). To fully validate this method, additional cell lines, both 
immortalized and primary, in various tissues need to be tested.   
 Cell death can take a number of routes, such as necrosis, apoptosis, or autophagy, 
to name a few (for review, see Galluzzi et al., 2012), whose time course after initial 
exposure can last anywhere from minutes to days (Lemasters et al., 1998). Irrespective of 
the cell death modality, the switch between cell death and survival revolves around the 
integration of signals at mitochondrial membranes that contribute to mitochondrial 
membrane permeability (MMP) (Kroemer et al., 2007). Since MMP is a major player in 
the eventual cellular fate decision of survival or death, monitoring protein signaling 
cascades that converge upon mitochondrial membranes is an advantageous approach. 
Forecasting a cell's eventual fate can be accomplished by monitoring the phosphorylation 
status of proteins that are relevant to survival and death pathways at critical signaling 
time-points following exposure to xenobiotics. While the minimum number of proteins 
necessary to forecast future cell death has yet to be determined, our proof of principle 
study included 19 judiciously selected phosphoproteins in a multiplexable and high-
throughput bead-based ELISA assay. In this work, we chose to cast a wide net on cell 
death and survival pathways at pre-selected time-points to capture critical processes 
responsible for determining the cell's eventual fate. The proteins selected for this study 
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Figure 2.6. Ingenuity pathway analysis of phosphoprotein responses. The most significant network 
interactions from the 19 different phosphoproteins measured and important intermediate proteins were 
compiled in IPA. Since the proteins included in the analyses did not change for all doses at both time 
points, only one dataset per inhibitor is shown in the figure. As examples, a) 50 µM MEK inh II at 20 
minutes post-exposure and b) 50 µM TDZD-8 at 40 minutes post-exposure are included in the figure 
above. Normalized phosphoproteins that were greater than control are shown in red and 
phosphoproteins that were less than control are shown in green. IPA analysis indicated that the most 
significant molecular and cellular function of both inhibitor datasets were cell death and survival; 
specifically, apoptosis, cell survival, and necrosis were the most significant biological functions of the 
proteins included in the analyses. 
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were confirmed to be most relevant to cell death (specifically apoptosis and necrosis) and 
survival by using Ingenuity Pathway Analysis (IPA)-constructed multidirectional 
interaction networks with biological function overlay (Figure 2.6a and b) to visualize the 
connectivity of the proteins and their association with various biological functions.  For 
future development of this approach, additional phosphoproteins or different 
combinations of phosphoproteins should be measured to determine the optimal number 
and type of protein to forecast eventual cellular fate. Additionally, this approach only 
monitored phosphoprotein responses to xenobiotic exposure. However, different types of 
post-translational modifications, such as glycosylation, methylation, or acetylation, may 
also be useful for this type of methodology.      
 While relative phosphoprotein responses of HepG2 cells to various doses of 
inhibitors at key time points post-exposure offer a wealth of information about these 
critical signaling events, a more digestible data platform and data transformation are 
required to construct the forecasted dose-response to TDZD-8 and MEK inh II exposure. 
Hierarchical cluster analysis using Ward's method produces clusters that minimize the 
variance within each cluster (Ward, 1963).  Going a step further, two-way cluster analysis 
allows for the simultaneous clustering of both variables in this paper (i.e., phosphoprotein 
response profiles and dose). In the first dimension, the protein responses across all doses 
(0 µM - 100 µM and theoretical infinite dose) are clustered to minimize the within-cluster 
variance and simultaneously in the second dimension, doses with similar phosphoprotein 
response profiles are clustered together. It is the latter dimension that provides useful 
distances based on the within-group minimized ANOVA sum of squares across all 
clusters. By including the vehicle control phosphoprotein responses (0 µM) and 
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theoretical infinite dose phosphoprotein responses, the forecasted dose-response range 
can be computed, regardless of the actual full dose-response curve (i.e., this circumvents 
the need to pre-determine exposure doses that go from 0 % cell death to 100 % cell 
death). Each replicate dose cluster's ANOVA sum of squares distances were placed in 
order of increasing dose (0 µM - theoretical infinite dose) and integrated across the 
dosing range to formulate the forecasted relative plasma membrane degradation dose-
response curve. While this method does not pinpoint the full intracellular mode(s) of 
action for the two inhibitors included in this study, the 24 hour relative plasma membrane 
degradation dose-response was accurately forecasted as early as 20 minutes post-
exposure to MEK inh II and 40 minutes post-exposure to TDZD-8 exposure. 
Additionally, the observed relative plasma membrane degradation at 20 minutes post-
exposure to MEK inh II and 40 minutes post-exposure to TDZD-8 has little to no death 
occurring. Therefore, the phosphoprotein responses at 20 minutes and 40 minutes post-
exposure are likely associated with the cell's own pharmacodynamic interpretation of 
exposure and eventual cell fate decision, as opposed to actual cell death occurring at this 
time point.   
 In conclusion, this approach offers several advantages over current methodologies 
to determine future xenobiotic toxicity: using extracellular techniques that do not disrupt 
the native intracellular biochemical processes to estimate ATP production relevant to 
critical signaling events, selecting phosphoproteins relevant to survival and/or death 
pathways at critical signaling time-points that may be predictive of the cell's eventual fate 
(i.e., 24 hours post-exposure), and using hierarchical cluster analysis to predict the 24 
hour relative plasma membrane degradation from early phosphoprotein responses. This 
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method has been shown to accurately forecast the eventual cellular fate of HepG2 cells 
exposed to two different xenobiotics, with disparate intracellular modes of action, and 
may theoretically work for any intracellular mode of toxicity or cell death modality. 
Finally, our results for this approach suggest that an analysis aggregating several different 
protein networks may be more informative of in vitro toxicity than any individual 
pathways or biomarkers. This has broad implications for many scientific fields, including 
toxicology and pharmacology. These advantages allow for future studies in a high-
throughput framework to quickly assess and forecast the eventual xenobiotic toxicity of 
cells in vitro. Additionally, the ability to identify early critical signaling events post-
exposure that are related to important cellular endpoints, such as survival or death, may 
significantly impact the pharmacological understanding of the therapeutic window for 
treatment strategies, and potentially alter the forecasted cellular fate by probing the 
endogenous signaling responses to treatments at these time points.      
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Forecasting cell death dose-response to mixtures in vitro 
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3. Forecasting cell death dose-response to mixtures in vitro
1
 
 Individuals are continuously exposed to complex chemical mixtures, whether they 
are derived from environmental or pharmaceutical (polypharmacy) exposures. While this 
is an everyday reality, most chemical risk assessments are carried out on a single 
chemical, or single-dose binary mixtures. Understanding and ultimately predicting 
chemical mixture effects could not only elucidate potential risk factors associated with 
exposures, but also offer the opportunity to develop a greater understanding of cellular 
mechanisms of environmental exposure and even drug discovery. Previously, we have 
shown that post-translational phosphorylation responses to chemical mixture exposures 
can be predicted in vitro using Bliss Independence (Boyd et al., 2013). We have also 
shown that 24 h in vitro cell death dose-response can be forecasted at significantly earlier 
time-points (as early as 20 min or 40 min, depending upon the exposure) by using two-
way cluster analysis of phosphorylation responses (Vrana et al., 2014). However, if both 
methodologies are combined, it may be possible to forecast 24 h mixture cytotoxicity 
without measuring the mixture itself;  ultimately representing a model capable of 
predicting mixture toxicity using only individual compound phosphoprotein responses of 
key kinases at critical signaling events. To this end, we have combined the two 
methodologies to potentially forecast mixture cell death dose-response using Bliss 
Independence-predicted phosphorylation values and compared those results to observed-
forecasted and observed values. To fully test this method, we used two different 
mixtures: Deguelin and KCN (both ETC inhibitors) and MEK inh II and TDZD-8 
                                                 
1
 Parts of this chapter have been published previously from Boyd, J., Vrana, J.A., Williams, H.N. (2013) In 
vitro approach to predict post-translational phosphorylation response to mixtures. Toxicology 313, 113-21. 
Reproduced with permission from Elsevier. 
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(disparate kinase inhibitors). The phosphoprotein targets used in this study are key 
kinases involved in cellular survival and/or death pathways. By monitoring the response 
of these phosphoproteins at critical signaling time-points, the eventual cellular fate may 
be forecasted. Additionally, by using Bliss Independence-predicted phosphoprotein 
responses for two-way cluster analyses, cytotoxicity in response to a potential mixture 
may be forecasted without experimentally measuring the mixture. 
 
3.1 Introduction 
Humans are continuously exposed to complex chemical mixtures, from the air we 
breathe and the water we drink to the medications we take daily. While this is an 
everyday reality, most chemical risk assessments are carried out on a single chemical, or 
single-dose binary mixtures (Cedergreen et al., 2008). Traditional risk assessment testing 
techniques involve screening potential agents with a single high dose exposure, using a 
suite of in vivo animal models and apical endpoint analyses, such as neurotoxicity or 
developmental toxicity, and narrowly-focused mode of action analysis, such as specific 
cytotoxicity or mutagenicity assays (Dix et al., 2007). This low-throughput approach that 
relies heavily on animal testing and high dose exposure analyses has created an enormous 
backlog of chemicals waiting to be evaluated for potential toxicity (Bushnell et al., 2010; 
Bhattacharya et al., 2011). This risk assessment crisis prompted the 2007 U.S. National 
Research Council (NRC) report, Toxicity Testing in the 21st Century: A Vision and a 
Strategy (NRC, 2007). In this report, the NRC proposed a paradigm shift from low-
throughput in vivo studies to new risk assessment strategies that utilizes high-throughput 
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in vitro screening assays to exploit early cellular changes (such as signaling pathway 
perturbations and alterations in cellular bioenergetics) to reveal mechanistic information 
about adverse or adaptive effects after xenobiotic exposure (Hartung, 2009; Krewski et 
al., 2010; Attene-Ramos et al., 2013). With this mechanistic information, better risk 
assessment models can be constructed for single chemical and mixture exposure in 
humans, greatly benefiting the public health sector.  
New risk assessment approaches would include a suite of assays that cast a wide 
net on early cellular changes, such as changes in cellular bioenergetics, and various 
pathway perturbations, such as alterations in post-translational modifications (PTMs) 
post-exposure, to fully understand the cellular response, whether that be adaptation after 
exposure to a new homeostatic state, or cell death (Andersen and Krewski, 2009). 
Understanding and eventually predicting chemical mixture effects could not only 
elucidate potential risk factors associated with exposures, but also offers the opportunity 
to estimate mixtures toxicity at various doses without measuring the actual mixture. With 
this new risk assessment methodology in mind, we have shown that early pathway 
perturbation responses, such as phosphorylation PTMs, to chemical mixture exposures 
(electron transport chain (ETC) inhibitors as well as broad kinase inhibitors) can be 
predicted in vitro using Bliss Independence (with accuracy > 77 %) (Boyd et al., 2013). 
We have also shown that 24 h in vitro cell death dose-response can be forecasted at early 
time points (as early as 20 min or 40 min, depending upon the exposure) by using two-
way cluster analysis of phosphorylation responses at time points relevant to changes in 
cellular bioenergetics and, consequently, perturbations in signal transduction (Vrana et 
al., 2014). The potential combination of these two methodologies may offer a new model 
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for risk assessment capable of harnessing early cellular changes post-exposure to predict 
potential mixtures effects related to cytotoxicity. From this approach, dose-response 
chemical mixture cytotoxic effects may be mathematically predicted without measuring 
the actual mixture. The approach presented in this chapter could be used to test the tens 
of thousands of chemicals currently used and predict all combinations at multiple doses 
that have the potential to be synergistic. This would then allow current risk assessment to 
narrow the experimental efforts to only those doses and chemicals of concern for further 
in vivo testing     
 In this proof-of-concept study, we have combined the two methodologies to 
forecast mixture cell death dose-response using Bliss Independence-predicted 
phosphorylation values and compared those results to observed phosphorylation 
response-forecasted cell death and observed cell death values. The inhibitors used as 
chemical mixtures in this proof of concept study are two mitochondrial electron transport 
chain (ETC) inhibitors, deguelin (0.01 - 100 µM) and KCN (0.01 - 100 µM), and two 
disparate kinase inhibitors, 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone, which is a 
MEK1 inhibitor, commonly referred to as MEK inh II (0.5 - 20 µM doses) and  the 
substrate-competitive GSK-3β inhibitor, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-
dione, commonly referred to as TDZD-8 (1 - 100 µM doses). These mixtures were 
chosen for their potential interaction and subsequent perturbation of mitochondrial 
bioenergetics (deguelin and KCN), as well as potential intracellular signaling network  
perturbations (MEK inh II and TDZD-8). The phosphoprotein targets used in this study 
are kinases involved in cellular survival and/or death pathways. By monitoring the 
response of these phosphoproteins at critical signaling time-points, the eventual cellular 
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fate may be forecasted. Additionally, by using Bliss Independence-predicted 
phosphoprotein responses for two-way cluster analyses, cell death in response to a 
potential mixture may be forecasted without experimentally measuring the mixture.  
  
3.2 Materials and Methods 
3.2.1 Materials - Deguelin and KCN     
  Deguelin (CAS 522-17-8) and KCN (CAS 151-50-8) were obtained from Sigma 
Aldrich (St. Louis, MO).  RPMI-1640 containing phenol red, RPMI-1640 without phenol 
red, sodium pyruvate, HEPES, L-glutamine, fetal bovine serum, and penicillin-
streptomycin were obtained from Invitrogen (Carlsbad, CA). HepG2 cells were obtained 
from American Type Culture Collection (Manassas, VA). BioPlex beads, lysis buffer, 
and reagents necessary for determination of relative phosphorylation were obtained from 
BioRad (Hercules, CA). Deionized water used in this study was prepared with the Milli-
Q Water System (Millipore, Bedford, MA). 
 
3.2.2 Materials - MEK inh II and TDZD-8 
 The chemicals 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8, CAS 
327036-89-5), Dulbecco's modified Eagle's medium (DMEM), sodium pyruvate, D-
glucose, L-glutamate, and sodium bicarbonate were obtained from Sigma Aldrich (St. 
Louis, MO). 2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone (MEK inh II, cas 623163-
52-0) was purchased from CalBiochem (La Jolla, CA, USA). HEPES was purchased 
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from Fisher Scientific (USA). Fetal bovine serum, Ethidium homodimer-1 cytotoxicity 
kit, ATP determination kit (luciferase assay), and penicillin-streptomycin were obtained 
from Invitrogen (Carlsbad, CA). HepG2 cells were obtained from American Type 
Culture Collection (Manassas, VA). Multiplex bead-based ELISA assays (beads, 
reagents, and lysis buffers) were purchased from Bio-Rad (Hercules, CA) and EMD 
Millipore (Billerica, MA). Deionized water used in this study was prepared with the 
Milli-Q Water System (Millipore, Bedford, MA). 
 
3.2.3 Cell culture   
 Human hepatocellular carcinoma-derived HepG2 cells were cultured in RPMI-
1640, supplemented with 1 mM sodium pyruvate, 5 mM HEPES, 2 mM L-Glutamine, 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin for deguelin 
and KCN experiments. For MEK inh II and TDZD-8 experiments, HepG2 cells were 
cultured in DMEM, supplemented with 2 g/L D-glucose, 2 mM L-Glutamate, 5 mM 
HEPES, 24 mM sodium bicarbonate, 1 mM sodium pyruvate, 10% fetal bovine serum, 
100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were maintained in a 
humidified atmosphere at 37°C, 5% CO2 and passaged at 80 % confluence. 
  
3.2.4 Dosimetry   
 For plasma membrane degradation assays, cells were seeded into clear-bottom, 
96-well black-sided plates at a concentration of 4 x 10
4
 cells per well in RPMI (or 
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DMEM for MEK inh II/TDZD-8) without phenol red and allowed to grow for 24 h 
before dosing. For deguelin and KCN multiplex phosphoprotein assays, cells were seeded 
in 96-well plates at a concentration of 4 x 10
4
 cells per well in RPMI without phenol red 
and allowed to grow for 24 h before dosing. For MEK inh II and TDZD-8 multiplex 
phosphoprotein assays, cells were seeded in 12-well plates at a concentration of 5 x 10
5
 
cells per well in DMEM without phenol red and allowed to grow for 24 h before dosing. 
Deguelin, TDZD-8, and MEK inh II dosing solutions were prepared so that resulting well 
concentrations would be < 1 % DMSO. KCN is water-soluable, therefore dosing 
solutions were prepared in water.  
 
3.2.5 Multiplex phosphoprotein assay - Deguelin and KCN mixtures 
 After 400 min of exposure to mixtures of deguelin (0.01 - 100 µM) and KCN 
(0.01 - 100 µM), cells were washed with ice cold PBS and lysed according to 
manufacturer's protocol. Total protein concentration was determined using the DC 
Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s instructions.  
Protein phosphorylation was determined by using the bead-based BioPlex suspension 
array system (Bio-Rad, Hercules, CA) and lysates were prepared according to the 
manufacturer’s protocol.  Beads and detection antibodies against phosphorylated ERK1/2 
(Thr202/Tyr204, Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα (Ser32/Ser36), 
JNK (Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK 
(Thr359/Ser363) were obtained from Bio-Rad (Hercules, CA).  Relative phosphorylation 
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was calculated by normalizing to control cells, which received dosing vehicle (<1% 
DMSO).  All experiments were performed in duplicate. 
 
3.2.6 Multiplex phosphoprotein assay - MEK inh II and TDZD-8 mixtures 
 After 20 min or 40 min of exposure to mixtures of MEK inh II (0.5, 1, 2, 5, 10, or 
20 µM) and TDZD-8 (1, 5, 10, 20, 50, or 100 µM), cells were washed with ice cold PBS 
and lysed according to manufacturer's protocol. Total protein concentration was 
determined using the DC Protein Assay (BioRad, Hercules, CA) according to the 
manufacturer’s instructions. Protein phosphorylation was determined by using the bead-
based BioPlex suspension array system (Bio-Rad, Hercules, CA) and lysates were 
prepared according to the manufacturer’s protocol.  Beads and detection antibodies 
against phosphorylated AKT (Ser473), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), 
HSP27 (Ser78), IκBα (Ser32/Ser36), JNK1/2 (Thr 183/Tyr185), MEK1 (Ser217/Ser221), 
and p38MAPK (Thr180/Tyr182) were obtained from Bio-Rad (Hercules, CA). Beads and 
detection antibodies against phosphorylated BAD (Ser 112), CREB1 (Ser133), IRS1 
(Ser636/Ser639), and p53(Ser46) were obtained from EMD Millipore. Relative 
phosphorylation was calculated by normalizing to control cells, which received dosing 
vehicle (<1% DMSO).  All experiments were performed in duplicate. 
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3.2.7 Plasma membrane degradation assay   
 To determine plasma membrane degradation of HepG2 cells exposed to mixtures 
of deguelin and KCN or MEK inh II and TDZD-8, the ethidium homodimer-1 (EthD-1) 
kinetic assay was used.  Twenty-four hours after seeding HepG2 cells (4 x 10
4
) in a 
black-sided clear-bottom 96 well plate, culture medium was aspirated and replaced with 
probe-containing culture medium (2 µM EthD-1).  Dead control wells were exposed to 
70% methanol and the plate was incubated for 30 min.  Following the 30 minute 
incubation, cells were challenged mixtures of deguelin (0.01 - 100 µM) and KCN (0.01 - 
100 µM) or mixtures of MEK inh II (0.5, 1, 2, 5, 10, or 20 µM) and TDZD-8 (1, 5, 10, 
20, 50, or 100 µM) and read immediately after dosing.  Fluorescent signal was obtained 
using an Infinite M1000 microplate reader (Tecan US, Raleigh NC) with excitation 
wavelength of 530 nm and emission wavelength of 645 nm, reading from the bottom 
every 10 min for 24 h after dosing.  Experiments were performed in duplicate.  Relative 
plasma membrane degradation was determined by normalizing to dead control (received 
70% methanol). Vehicle control wells did not exceed 10 % death.   
 
3.2.8 Statistical analysis 
 Correlation analysis for observed phosphoprotein mixture responses and Bliss 
independence-predicted phosphoprotein mixture responses were determined using SAS 
JMP V12Pro (Cary, NC). Two-way hierarchical cluster analyses with Ward's minimum 
variance were determined by using SAS JMP V12Pro (Cary, NC). Statistical significance 
for plasma membrane degradation (observed, forecasted, and Bliss-forecasted) were 
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determined by using a two-way analysis of variance (ANOVA) with Bonferroni post-test.  
A difference of P < 0.05 was considered statistically significant.  For plasma membrane 
degradation and relative phosphorylation data, error bars reflect standard error of the 
mean (S.E.M.).   
 
3.3 Results  
3.3.1 Using Bliss independence (response addition) to predict relative phosphorylation 
during critical signaling events 
 For this proof-of-concept study, we first determined the relative phosphorylation 
of HepG2 cells exposed to individual chemicals of interest. Previously, we estimated a 
critical signaling event for deguelin and KCN at 400 min post-exposure using HepG2 
cells and relative oxygen consumption observations (Boyd et al., 2013). Since alterations 
in oxygen consumption (cellular respiration) may suggest early perturbations of cellular 
bioenergetics and potentially adverse effects, we chose a time point where all dosing 
conditions experienced the highest degree of change. Previously, we also identified early 
critical signaling events at 20 min and 40 min post-post exposure to MEK inh II and 
TDZD-8, respectively, in HepG2 cells using our published method for estimating ATP 
generation (Vrana et al., 2014). At the identified time points post-exposure, a snapshot of 
the toxicodynamic response to deguelin and KCN or MEK inh II and TDZD-8 exposure 
can be determined with a high-throughput approach. Inclusion of valuable proteins that 
cast a wide net on cell death or survival pathways at this time point is necessary to 
capture intracellular processes related to adverse or adaptive perturbation responses.  
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After exposure to cellular stressors (e.g., xenobiotics, endogenous molecules), many 
kinase pathways converge upon mitochondria, which can result in mitochondrial 
membrane permeabilization (MMP) mediated death (Kroemer et al., 2007; Rehm et al., 
2009). From this, we chose to narrow the list of potential proteins to those that are only a 
few kinase steps removed from key survival or death proteins that are known to alter 
mitochondrial activity. To this end, a multiplex bead-based ELISA assay was designed 
and used to simultaneously determine different protein phosphorylation responses for 
deguelin and KCN (Figure 3.1) and MEK inh II and TDZD-8 (Figures 3.2) at time points 
relevant to their respective critical signaling events.  Cells were lysed and measured for 
phosphoprotein response at the pre-selected critical signaling time points: 400 min post-
exposure to deguelin and KCN alone (Figure 3.1) or as a chemical mixture (Appendix 
3.1) and 20 min and 40 min post-exposure to MEK inh II and TDZD-8 alone (Figure 2.3) 
or as a chemical mixture (Appendix 3.2-3.3). Phosphoprotein responses were determined 
Figure 3.1. Relative phosphorylation responses of HepG2 cells exposed to deguelin or KCN. 
Relative protein phosphorylation was determined by dosing HepG2 cells with various doses of deguelin 
(0.01 - 100 µM) or KCN (0.01 - 100 µM) and lysing the cell membrane at 400 min post-exposure. 
Relative phosphorylation was calculated by normalizing to vehicle controls. Error bars reflect S.E.M. 
Assay was performed in duplicate. 
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relative to control, which received dosing vehicle (< 1% DMSO for deguelin, MEK inh 
II, and TDZD-8, or water for KCN). 
  
 
 
Figure 3.2. Relative phosphorylation responses of HepG2 cells exposed to MEK inh II or TDZD-8. 
Relative protein phosphorylation was determined by dosing HepG2 cells with various doses of MEK inh 
II (0.5, 1, 2, 5, 10, 20 µM; left graphs) or TDZD-8 (1, 5, 10, 20, 50, 100 µM; right graphs) and lysing the 
cell membrane at 20 min (top graphs) or 40  min (bottom graphs) post-exposure. Relative 
phosphorylation was calculated by normalizing to vehicle controls. Error bars reflect S.E.M. Assay was 
performed in duplicate. 
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Figure 3.3. Deguelin and KCN mixture 
correlation. Correlation plot of observed 
and Bliss Independence-predicted 
phosphoprotein mixture responses at 400 
min post-exposure. Data points represent 
the mean of the mixture response. For this 
mixture data set, predicted values were 
strongly correlated to observed values, 
r(200) = 0.904, P < .0001. 
Figure 3.4. MEK inh II and TDZD-8 mixture 
correlation (20 min). Correlation of observed and 
Bliss Independence-predicted phosphoprotein 
mixture responses at 20 min post-exposure. Data 
points represent the mean of the mixture response. 
For this mixture data set, predicted values were 
moderately correlated to observed values, r(432) = 
0.657, P < .0001. 
Figure 3.5. MEK inh II and TDZD-8 mixture 
correlation (40 min). Correlation of observed and 
Bliss Independence-predicted phosphoprotein 
mixture responses at 40 min post-exposure. Data 
points represent the mean of the mixture response. 
For this mixture data set, predicted values were 
weakly correlated to observed values, r(428) = 
0.311, P < .0001. 
  For the same mixtures and dosing 
regimen, we also predicted relative 
phosphorylation responses at the key time 
points of interest using Bliss independence 
(Appendix 3.1-3.3), as previously shown in 
Boyd, et al., 2013. Experimentally 
determined phosphoprotein responses of 
individual chemicals were used to calculate 
predicted values at the time points of interest. 
To determine the accuracy of our prediction 
method, we used correlation analysis for 
observed and predicted relative 
phosphorylation responses (Figures 3.3-3.5). Prediction of relative phosphoprotein 
responses to deguelin and KCN mixtures at 400 min post-exposure (Figure 3.3) were 
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strongly correlated to experimentally determined mixture phosphoprotein responses (r = 
0.904, N = 200, P < 0.0001). Prediction of relative phosphoprotein responses to MEK inh 
II and TDZD-8 mixtures at 20 min post-exposure (Figure 3.4) were moderately correlated 
to experimentally determined mixture phosphoprotein responses (r = 0.657, N = 432, P < 
0.0001). Prediction of relative phosphoprotein responses to MEK inh II and TDZD-8 
mixtures at 40 min post-exposure (Figure 3.5) were weakly correlated to experimentally 
determined mixture phosphoprotein responses (r = 0.311, N = 428, P < 0.0001). The 
number of data points included in the correlation analysis of MEK inh II and TDZD-8 
mixtures at 40 min were 428 instead of 432 due to 4 protein-dose combinations having 
instrumental error, which in this instance, was from bead aggregation. 
  
3.3.2 Forecasting mixtures dose-response with hierarchical cluster analysis  
 By monitoring or predicting the phosphorylation response of proteins involved in 
Figure 3.6. Observed phosphoprotein responses 
for PM degradation forecast. Cluster distances to 
forecast PM degradation from observed 
phosphoprotein responses to mixtures of deguelin 
and KCN 400 min post-exposure were calculated 
with the unsupervised Ward two-way hierarchical 
clustering method. PM degradation dose-response 
curves were calculated using the equation above. 
 
Figure 3.7. Bliss independence-predicted 
phosphoprotein responses for PM degradation 
forecast. Cluster distances to forecast PM 
degradation from predicted phosphoprotein 
responses to mixtures of deguelin and KCN 400 
min post-exposure were calculated with the 
unsupervised Ward two-way hierarchical 
clustering method. PM degradation dose-response 
curves were calculated using the equation above. 
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cellular survival and/or death pathways at early time-points, the fate of the cell may be 
forecasted. In order to accomplish this, we used our previously published method (Vrana 
et al., 2014), which incorporates two-way cluster analysis with Ward's minimum variance 
and a transformation of the cluster distances to yield a relative cell death dose-response 
(for example data analysis, see Figures 3.6-3.7). From this data, relative plasma 
membrane degradation forecasts can be determined for observed phosphoprotein 
responses and Bliss independence-predicted responses, and compared to experimentally 
determined relative plasma membrane degradation (Figure 3.8-3.9).  
 
Figure 3.8. Relative PM degradation (predicted and observed) of HepG2 cells at 400 min post-exposure to 
deguelin and KCN.  Relative plasma membrane (PM) degradation dose-response plots depicting the 24 h 
observed, 24 h cluster forecasted PM degradation from observed phosphorylation values at 400 min post-
exposure, and 24 h cluster forecasted PM degradation from Bliss Independence-predicted phosphorylation values 
at 400 min post-exposure.  Forecasted relative PM degradation responses that are significantly different from 
observed 24 h PM degradation responses are marked with * (P < .05), ** (P < .01), or *** (P < .001). Observed 
relative PM degradation at 400 min post-exposure had less than 10 % toxicity for all dose combinations 
measured (data not shown). Forecasted relative PM degradation responses from 400 min observed 
phosphorylation responses that were statistically different from Bliss-forecasted relative PM degradation 
responses from 400 min predicted phosphoprotein responses were indicated with # (P < .05). Statistical 
significance was determined by using two-way ANOVA with Bonferroni post-test. 
 
93 
 
 
Figure 3.9.  Relative PM degradation (predicted and observed) of HepG2 cells at 20 and 40 min post-exposure 
to MEK inh II and TDZD-8. Relative plasma membrane (PM) degradation dose-response plots depicting the 24 h 
observed, 24 h cluster forecasted PM degradation from observed phosphorylation values at 20 min (red) and 40 min 
(blue) post-exposure, and 24 h cluster forecasted PM degradation from Bliss Independence-predicted phosphorylation 
values at 20 min (purple) and 40 min (green) post-exposure.  Forecasted (from Bliss independence-predicted 
phosphoprotein responses and observed phosphoprotein responses) relative PM degradation responses that are 
significantly different from observed 24 h PM degradation responses are marked with * (P < .05), ** (P < .01), or 
*** (P < .001), corresponding to their respective colors. Statistical significance was determined by using two-way 
ANOVA with Bonferroni post-test. 
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3.4 Discussion 
 Humans are continuously exposed to a large number of chemicals, such as food, 
air, vitamin supplements, and pharmaceuticals, at various doses, and through a variety of 
exposure routes on a daily basis (Groten et al., 2001). Understanding and ultimately 
predicting the possible combined effects of a given mixture exposure is necessary for risk 
assessment toxicology. The current backlog of tens of thousands of chemicals entering 
the environment for which there is limited or no toxicity information has initiated a 
paradigm shift in traditional toxicity testing (Wilson and Schwarzman, 2009; Judson et 
al., 2010; Kavlock et al., 2012; Sipes et al., 2013). This new push towards high-
throughput in vitro approach would take advantage of early cellular perturbations post-
exposure associated with toxicity endpoints in human cell lines and tissues to elucidate 
mechanistic information regarding the mode(s) of action for a potential xenobiotic or 
mixture (Attene-Ramos et al., 2013). To this end, we combined our two previous 
prediction models to develop this proof-of-concept study to monitor early cellular 
changes relevant to signaling perturbations post-exposure for mixtures model 
development and potential toxicity predictions.  
By combining these two methodologies, we hope to open the door to the 
possibility of predicting cytotoxicity in response to an exposure of any chemical mixture.  
For the Bliss-independence predicted phosphorylation responses, the prediction model 
worked exceptionally well for deguelin and KCN mixtures as well as MEK inh II and 
TDZD-8 mixtures after 20 min of exposure. However, MEK inh II and TDZD-8 
predictions were weakly (albeit significantly) correlated to experimentally determined 
mixture responses after 40 min of exposure. This model for early PTM toxicodynamic 
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responses could greatly benefit from further development since it worked well for certain 
protein-dose combinations at discrete time points but missed others, especially the MEK 
inh II and TDZD-8 phosphoprotein responses 40 min post-exposure. As discussed 
previously in Chapter 1, mixtures prediction models often fail when an observed mixture 
acts synergistically (Meled et al., 1998; Forget et al., 1999), antagonistically (Posthuma 
et al., 1997; Van Gestel and Hensbergen, 1997), or experiences dose-dependent subtle 
interactions (e.g., synergy for low dose mixtures and antagonist for high dose mixtures) 
(Gennings et al., 2002; Jonker et al., 2004).  
In this study, we also utilized our previously developed cytotoxicity forecasting 
model to potentially predict 24 h plasma membrane degradation (cell death) with early 
toxicodynamic perturbations. The deguelin and KCN mixtures (both observed 
phosphorylation response forecasted and Bliss-predicted phosphorylation response-
forecasted) were only 30 and 40 % accurate for prediction of cytotoxicity, respectively.  
However, most low dose deguelin mixtures were accurately predicted (0.01 and 0.1 µM). 
It is important to note that both models for deguelin and KCN mixtures were not 
significantly different from each other (only 2 of 25 dose combinations were significantly 
different, P < .05), suggesting that the Bliss Independence-predicted phosphoprotein 
responses could be used in lieu of actual phosphoprotein mixture responses to forecast 
cytotoxicity. For MEK inh II and TDZD-8 mixtures forecasts (20 min), both observed 
phosphorylation response forecasted and Bliss-predicted phosphorylation response-
forecasted were 75 and 50 % accurate for prediction of cytotoxicity, respectively. Also, 
for MEK inh II and TDZD-8 mixtures forecasts (40 min), both observed phosphorylation 
response forecasted and Bliss-predicted phosphorylation response-forecasted were 77 and 
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49 % accurate for prediction of cytotoxicity, respectively. The early cellular changes 
measured (i.e., phosphorylation responses of kinases related to cell death and/or survival 
pathways) at 20 min post exposure were better for predicting cytotoxicity than at 40 min 
post-exposure to mixtures of MEK inh II and TDZD-8. This shows that appropriate 
selection of early time points, as well as judiciously selected phosphoproteins may 
improve prediction models. Most imporantly, the forecasted 24 h PM degradation using 
Bliss-independence predicted phosphoprotein responses accurately forecasted 
cytotoxicity (77 % and 49 % for 20 min and 40 min data, respectively).  This suggests 
that cytotoxicity dose-response of mixtures can be estimated without measuring the 
actual mixture. The mixture predictions for MEK inh II and TDZD-8 were much more 
accurate than the deguelin and KCN mixture predictions (49 – 77 % vs 30 – 40 %). This 
could be due to the inclusion of 12 phosphoproteins for MEK inh II and TDZD-8 
mixtures as opposed to the 8 phosphoproteins for deguelin and KCN. Additionally, MEK 
inh II and TDZD-8 mixture critical signaling time points were selected from estimated 
intracellular ATP, whereas deguelin and KCN mixture critical signaling time points were 
selected from oxygen consumption alone.  
Possible improvements to this approach could be in the type and number of PTMs 
to measure for early cellular perturbations post-exposure. Previously, our forecast model 
using individual compounds was very successful by using 19 phosphoprotein responses. 
However, in this study, only 8 and 12 phosphoproteins were included for mixture 
predictions. Future optimization of the number and identification of proteins necessary 
for accurate predictions will dramatically improve our model for cytotoxicity forecasting. 
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The initial success of this proof-of-concept approach suggests that high-
throughput in vitro assays incorporating a wide range of doses (low, moderate, and high) 
and early cellular changes to predict individual chemical and mixtures toxicity is 
exceedingly advantageous. We believe that this will greatly impact xenobiotic high-
throughput mixtures risk assessment in vitro, as well as pharmaceutical adverse drug 
reaction analyses.  
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Appendix 3.1 - Observed relative phosphorylation of deguelin and KCN mixtures 
(400 min post-exposure) 
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Deguelin + 0.1 M KCN (400 min)
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Deguelin + 1 M KCN (400 min)
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Deguelin + 10 M KCN (400 min)
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Deguelin + 100 M KCN (400 min)
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Appendix 3.2 - Observed relative phosphorylation of MEK inh II and TDZD-8 
mixtures (20 min post-exposure) 
MEK inh II + 1 M TDZD-8 (20 min)
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MEK inh II + 5 M TDZD-8 (20 min)
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MEK inh II + 10 M TDZD-8 (20 min)
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MEK inh II + 20 M TDZD-8 (20 min)
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MEK inh II + 50 M TDZD-8 (20 min)
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MEK inh II + 100 M TDZD-8 (20 min)
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Appendix 3.3 - Observed relative phosphorylation of MEK inh II and TDZD-8 
mixtures (40 min post-exposure) 
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MEK inh II + 5 M TDZD-8 (40 min)
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MEK inh II + 10 M TDZD-8 (40 min)
0.5 1 2 5 10 20
0
2
4
6
8
10
20
30
40
50
AKT
ERK1/2
HSP27
IkBa
IRS1
MEK1
p53
p90RSK
BAD
CREB
p38MAPK
JNK
AKT bliss
ERK bliss
HSP27 bliss
IkBa bliss
IRS1 bliss
MEK1 bliss
p53 bliss
p90rsk bliss
BAD bliss
CREB bliss
p38MAPK bliss
JNK bliss
MEK inh II (M)
R
e
la
ti
v
e
 P
h
o
s
p
h
o
ry
la
ti
o
n
 
 
114 
 
MEK inh II + 20 M TDZD-8 (40 min)
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MEK inh II + 50 M TDZD-8 (40 min)
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MEK inh II + 100 M TDZD-8 (40 min)
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Chapter 4 
Using mixtures to ameliorate undesired side-effects of 
deguelin 
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4. Using mixtures to ameliorate undesired side-effects of deguelin
1
 
 The pharmaceutical world has greatly benefited from the well-characterized 
structure-function relationships of toxins with endogenous biomolecules, such as ion-
channels, receptors, and signaling molecules. Thus, therapeutics derived from toxins have 
been aggressively pursued. However, the multifunctional role of various toxins may lead 
to undesirable off-target effects, hindering their use as therapeutic agents. In this paper, 
we suggest that previously unsuccessful toxins (due to off-target effects) may be revisited 
with mixtures by utilizing the pharmacodynamic response to the potential primary 
therapeutic as a starting point for finding new targets to ameliorate the unintended 
responses. In this proof of principle study, the pharmacodynamic response of HepG2 
cells to a potential primary therapeutic (deguelin, a plant-derived chemopreventive agent) 
was monitored, and a possible secondary target (p38MAPK) was identified. As a single 
agent, deguelin decreased cellular viability at higher doses ( > 10 µM), but inhibited 
oxygen consumption over a wide dosing range (1.0 – 100 µM). Our results demonstrate 
that inhibition of oxygen consumption is related to an increase in p38MAPK 
phosphorylation, and may only be an undesired side effect of deguelin (i.e., one that does 
not contribute to the decrease in HepG2 viability). We further show that deguelin’s 
negative effect on oxygen consumption can be diminished while maintaining efficacy 
when used as a therapeutic mixture with the judiciously selected secondary inhibitor 
(SB202190, p38MAPK inhibitor). These preliminary findings suggest that an 
endogenous response-directed mixtures approach, which uses a pharmacodynamic 
                                                 
1
 Parts of this chapter have been published previously, either in part or in full, from Vrana, J.A., Boggs, N., 
Currie, H.N., Boyd, J. (2013) Amelioration of an undesired action of deguelin. Toxicon 74, 83-91. 
Reproduced with permission from Elsevier. 
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response to a primary therapeutic to determine a secondary target, allows previously 
unsuccessful toxins to be revisited as therapeutic mixtures. 
 
4.1 Introduction 
The well-characterized structure-function relationships of toxins, such as snake 
venoms and plant-derived toxins, have led to major advances in understanding normal 
and disease state physiology, as well as the development of pharmacological regimens 
based on the structures of various toxins (McCleary and Kini, 2012).  One such example 
is captopril, an angiotensin-converting enzyme inhibitor to treat hypertension that is 
based on bradykinin-potentiating factor (BPF) isolated from the Brazilian pit viper 
Bothrops jararaca (Ferreira, 1965).  Captopril has also been used in combination with 
marimastat (a matrix metalloproteinase inhibitor) and fragmin (a low molecular weight 
heparin approved by the U.S. FDA) as an antiangiogenesis therapeutic mixture for 
patients with advanced stage cancer (Jones et al., 2004).  From the successes of captopril, 
among many other therapeutics derived from toxins, natural toxin-based pharmacology 
has been aggressively pursued (Koh and Kini, 2012).  
Previously known for their success as insecticides and fishing poisons, plant-
derived rotenoids, such as deguelin, have been investigated for their potential use as 
chemopreventive (designed to delay the onset of cancer) and chemotherapeutic (designed 
to destroy cancer after it appears) agents (Kim et al., 2008; Aggarwal et al., 2004).  
Deguelin, a natural isoflavonoid isolated from the root of Lonchocarpus utilis and 
Lonchocarpus urucu (Caboni et al., 2004), inhibits NADH:ubiquinone oxidoreductase 
(complex I) of the mitochondrial electron transport chain (ETC), HSP90, and AKT (Lee 
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et al., 2005; Oh et al., 2007, 2008; Peng et al., 2007).  As a fishing poison, rotenoids are 
often used due to their inhibition of cellular respiration via inhibition of complex I of the 
ETC (Neuwinger, 2004).  Inhibition of respiration in cells results in tissue asphyxia and 
consequently organ paralysis (Neuwinger, 2004).  As a chemopreventive agent, 
rotenoids, specifically deguelin, have shown promise for a variety of cancer types (Chun 
et al., 2003; Murillo et al., 2002; Peng et al., 2007; Udeani et al., 1997).  Unfortunately, 
when used as a chemotherapeutic, rotenoids have exhibited undesirable side effects, such 
as respiratory depression and cardiotoxicity, presumably due to a decrease in cellular 
oxygen consumption caused by inhibition of complex I (Lee, 2004).  Additionally, 
deguelin has been shown to induce a Parkinson's disease-like syndrome in rats when 
administered in high doses, which is also potentially related to activity at complex I 
(Caboni et al., 2004). These undesired side effects related to complex I inhibition have 
hindered deguelin’s use as a chemotherapeutic agent (Agarwal and Deep, 2008; Fang and 
Casida, 1998).
 
 While deguelin has inherent faults that diminish its legitimacy as a 
chemotherapeutic agent, it may still hold promise as a potential therapeutic if combined 
with another xenobiotic.  In recent years, using a combinatorial/mixtures approach with 
targeted kinase therapeutics has shown promise as an effective strategy (Engelman et al., 
2007; Ma et al., 2005; Namiki et al., 2006; Stommel et al., 2007; Yasui et al., 2007) 
because many mechanisms for cell survival rely on intricate and sophisticated 
intracellular signaling networks, making single-point inhibition impractical for treatment 
(Fitzgerald et al, 2006; Toschi and Janne, 2008).  The initial pharmacodynamic response 
to xenobiotic insult is primarily coordinated by signal transduction networks, which 
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typically follow a simple framework: the phosphorylation/dephosphorylation cycle 
mediated by kinases and phosphatases (Kholodenko, 2006; Sauro and Kholodenko, 
2004).  Since a typical cellular response to exposure involves the integration of many 
kinases into pathways for a coordinated response, this enzyme class make advantageous 
targets for a mixtures approach (Cohen, 2002; Collins and Workman, 2006; Dancey and 
Sausville, 2003). 
 There are several different strategies for determining possible mixtures therapies 
for kinase targets (Jackson, 1993).  One strategy involves the simultaneous inhibition of a 
single target using two or more compounds, while another strategy utilizes two inhibitors 
to attack two different proteins on a linear pathway (e.g. mitogen-activated protein kinase 
cascade) (Fitzgerald et al., 2006).  A drawback to these mixtures approaches is that prior 
knowledge of the network and kinases of interest are required to select which inhibitors 
to use.  This paper suggests an alternative strategy: instead of selecting mixtures based on 
previously known mechanisms and complex networks that may not fit the cell line or 
disease of interest, the endogenous response of the cell to a primary therapeutic may be 
used to select the secondary target of interest.  By monitoring the endogenous response of 
the network while under duress from a primary therapeutic, the cell’s alternate mode of 
survival can be exposed, and a second inhibitor may be selected for a more effective 
mixtures therapeutic strategy.  By utilizing the endogenous response to primary 
therapeutic, undesirable effects (such as decreased oxygen consumption following 
exposure to deguelin) may be targeted for amelioration.  Overall, this strategy holds 
promise for potentially maintaining efficacy of an initial therapeutic (deguelin) while 
reducing side effects for improved patient outcome.   
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 In this study, we investigated the endogenous response of HepG2 cells, a human 
hepatocellular carcinoma-derived cell line, to a primary therapeutic (deguelin) at varying 
doses to determine a potential secondary target for a beneficial therapeutic mixture.  We 
selected the HepG2 cell line as our model in vitro system due to the central role that the 
liver plays in xenobiotic biotransformation after exposure (Mersch-Sundermann, et al., 
2004).  Most importantly, the HepG2 cell line retains endogenous xenobiotic 
metabolizing enzymes, whereas primary hepatocyte culture typically loses these vital 
enzymes (Knasmuller, et al., 1998). We monitored the response of HepG2 cells to 
deguelin by determining 24 hour viability and kinetically measuring oxygen consumption 
over 24 hours.  From this data, we found a critical shift in oxygen consumption at 400 
minutes post-dose that spanned several doses.  At this time-point, we monitored the 
relative post-translational phosphorylation of 8 proteins involved in cell proliferation or 
apoptotic signal transduction cascades. From this phosphorylation response data, we 
selected p38MAPK as a secondary target, and used a specific p38MAPK inhibitor 
(SB202190) in combination with deguelin to possibly alter the overall cellular response 
to deguelin.  We found that by using an endogenously selected therapeutic mixture, 
deguelin’s inhibition of oxygen consumption was diminished while maintaining efficacy.  
This proof of principle study shows that by using an endogenous response-directed 
mixtures approach, previously unsuccessful toxins as a primary therapeutic may be 
revisited.  
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4.2 Materials and Methods 
4.2.1 Materials   
 Deguelin (CAS no. 522-17-8) and SB202190 (CAS no. 152121-30-7) were 
obtained from Sigma Aldrich (St. Louis, MO).  RPMI-1640 containing phenol red, 
RPMI-1640 without phenol red, sodium pyruvate, HEPES, L-glutamine, fetal bovine 
serum, and penicillin-streptomycin were obtained from Invitrogen (Carlsbad, CA). Cell 
lines and MTT assay kits were obtained from American Type Culture Collection 
(Manassas, VA).  MitoXpress oxygen probe was obtained from Luxcel Corporation 
(Cork, Ireland).  BioPlex beads, lysis buffer, and reagents necessary for determination of 
relative phosphorylation were obtained from BioRad (Hercules, CA). 
 
4.2.2 Cell culture   
 Human hepatocellular carcinoma-derived HepG2 cells were cultured in RPMI-
1640, supplemented with 1 mM sodium pyruvate, 5 mM HEPES, 2 mM L-Glutamine, 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were 
maintained in a humidified atmosphere at 37°C, 5% CO2 and passaged at 80 % 
confluence.  
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4.2.3 Dosimetry   
 Cells were seeded into clear-bottom, black-sided 96-well plates at a concentration 
of 4 x 10
4
 cells per well in RPMI-1640 without phenol red and allowed to grow for 24 
hours before dosing.  Media was then aspirated from wells and cells were challenged 
with varying doses of single and mixed compounds in fresh media.  Compounds were 
prepared so that resulting well concentrations would be <1% DMSO and 0.01 µM to 100 
µM (deguelin) and 350 nM (SB202190). 
 
4.2.4 MTT assay  
 After 24 hours of exposure to single compounds or mixtures, cell viability was 
determined using the MTT (3-(4,5-dimethyl)-2,5-diphenyl tetrazolium bromide) assay, 
according to the manufacturer’s protocol. The assay is based on the reduction of 
tetrazolium MTT to formazan by metabolically active cells, in part by the action of 
dehydrogenase enzymes, to generate reducing equivalents such as NADH and NADPH. 
Briefly, MTT reagent was added to the wells of the microplate, and after two hours of 
incubation at 37°C, intracellular formazan crystals were solubilized with the provided 
detergent solution.  Absorbance values were obtained using the Safire2 microplate reader 
(Tecan US, Raleigh, NC) with a measurement wavelength of 570 nm and a reference 
wavelength of 700 nm, read from the bottom.  Experiments were each performed at least 
in triplicate.  Percent viability was calculated by normalizing to controls, which received 
dosing vehicle (1% DMSO).   
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4.2.5 Oxygen consumption assay  
 Immediately after dosing with single compounds or mixtures, cellular oxygen 
consumption was assessed using the MitoXpress probe, according to manufacturer’s 
protocol.  Briefly, oxygen-sensitive probe was diluted to a stock concentration of 1μM, 
and stock probe was diluted 1:15 in each well of a 96-well plate containing cells; 100μL 
of pre-warmed mineral oil was also added to each well to block ambient oxygen from the 
cells.  After pre-warming the plates at 37°C for 1 hour, cells were challenged with 
varying doses of deguelin alone or in combination the IC50 of SB202190 (350nM).  
Immediately following addition of compound(s), oxygen consumption was determined by 
measuring fluorescence.  Fluorescent signal was obtained using the Infinite M1000 
microplate reader (Tecan US, Raleigh NC) with excitation wavelength of 380 nm and 
emission wavelength of 650 nm, reading from the bottom every 10 minutes for 24 hours 
after dosing.  Experiments were performed in quadruplicate.  Relative oxygen 
consumption was calculated by normalizing to controls, which received dosing vehicle 
(1% DMSO).   
 
4.2.6 Bio-Plex Multiplex Immunoassay 
 After 400 minutes of exposure (Boyd et al., 2012) to increasing doses of deguelin 
(0.01, 0.1, 1.0, 10, 100 µM) in 1% DMSO alone, or in combination with IC50 of 
SB202190 (350nM), cells were lysed using lysis buffer (BioRad, Hercules, CA) with 
500µM phenylmethanesulfonylfluoride (PMSF) (Sigma, St. Louis, MO) and phosphatase 
inhibitors (BioRad, Hercules, CA).  Total protein concentration was determined using the 
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DC Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s instructions.  
Protein phosphorylation was detected using multiplex bead-based BioPlex suspension 
array system (Bio-Rad, Hercules, CA) and lysates were prepared according to the 
manufacturer’s protocol.  Beads and detection antibodies against phosphorylated ERK1/2 
(Thr202/Tyr204, Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα (Ser32/Ser36), 
JNK (Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK 
(Thr359/Ser363)  were obtained from Bio-Rad (Hercules, CA).  Relative phosphorylation 
was calculated by normalizing to control cells, which received dosing vehicle (1% 
DMSO).  All experiments were performed in duplicate.   
 
4.2.7 Statistical Analysis 
 Dose-response curves for MTT assays were generated by best-fit Hill-plot 
regression of scatter plot data using Prism V5 (Graphpad Software, San Diego, CA). 
Oxygen consumption curves were generated by choosing the best-fit polynomial 
regression of scatter plot data using Prism V5 (Graphpad Software, San Diego, CA). The 
time point of interest (400 min) was selected using SAS JMP V8 (Cary, NC) where the 
change in the slope of the oxygen consumption curve reached a minimum for most 
exposures.  Statistical significance for viability and relative phosphorylation was assessed 
by using a two-way analysis of variance (ANOVA) with Bonferroni post-test.  Statistical 
significance for oxygen consumption (a kinetic assay) was assessed by using a Kruskal-
Wallis nonparametric test with Dunns post-test.  A difference at P < 0.05 level was 
considered statistically significant.  For viability and relative phosphorylation data, error 
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Figure 4.1.  Percent viability of HepG2 cells in response to 24 hour exposure of 0.01 – 100 µM 
deguelin. Viability, shown as % viability, was measured as in Methods and was calculated relative to 
control cells which received dosing vehicle (<1% DMSO) only.  Dose-response curve was generated 
by a best-fit Hill-plot regression of scatter plot data.  Error is reported as ± standard error of the mean 
(SEM). 
bars reflect standard error of the mean.  For oxygen consumption curves (best-fit 
polynomial regression), error was reported at the 95% confidence interval.  
 
4.3 Results  
4.3.1 Deguelin as a monotherapy 
 To determine the overall effect of deguelin alone, HepG2 cells were exposed to 
log doses of deguelin (0.01 – 100 µM) and viability at 24 hours post-dose was measured 
using the MTT assay (shown in Figure 4.1).  Our viability data suggests that deguelin is 
effective at doses greater than 10µM (EC50 = 45 ± 1 µM).   
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4.3.2 HepG2 viability (in response to 
deguelin) may not be directly 
associated with O2 consumption 
 To better relate deguelin's 
inhibition of oxygen consumption to 
endpoint viability, we kinetically 
measured the oxygen consumption of 
HepG2 cells in response to deguelin 
over 24 hours post-dose, as shown in 
Figure 4.2, using the MitoXpress 
oxygen consumption assay.  From 
Figure 4.2, oxygen consumption 
decreased when in the presence of 1.0 
– 100 µM doses of deguelin (as 
compared to controls, represented as percent oxygen consumption). A Kruskal-Wallis 
nonparametric test with Dunns post-test was used to compare oxygen consumption 
responses to various doses.  The oxygen consumption responses at all doses were 
statistically different (P < 0.05) from each other except for 1.0 µM vs 10 µM and 10 µM 
vs 100 µM.  Most importantly, there is a clear separation in oxygen consumption 
responses between two dosing groups: the lowest doses (0.01 and 0.1 µM) and the higher 
doses (1.0 – 100 µM).  Since our oxygen consumption data at these doses does not seem 
to correspond with our MTT assay (which demonstrated no decrease in viability for the 
1.0 and 10 µM doses), the inhibition of oxygen consumption may not be directly 
Figure 4.2.  Percent oxygen consumption of HepG2 
cells in response to 0.01 – 100 µM deguelin.  Oxygen 
consumption response of HepG2 cells to increasing doses 
of deguelin (shown in shades of gray) measured over 24 
hours.  Oxygen consumption was measured using 
MitoXpress extracellular assay as outlined in section 2.5.  
Percent oxygen consumption is shown relative to control 
cells which received dosing vehicle (<1% DMSO) only.  
Oxygen consumption curves were generated using a best-
fit polynomial function with error bars reflecting the 95% 
confidence intervals.  Vertical line at 400 minutes was 
selected as the time-point of greatest disparity in oxygen 
consumption. 
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associated with 24 hour HepG2 viability in response to deguelin.  Furthermore, for the 
lower doses of deguelin (0.01 and 0.1 µM), oxygen consumption actually increases 
relative to controls until about 400 minutes post-exposure; at this time-point, oxygen 
consumption decreases, ultimately returning to control levels.  Therefore, 400 minutes 
appears to be an interesting time point post-exposure that results in the greatest disparity 
in oxygen consumption between high and low doses. Since the full dosing regimen of 
deguelin indicated 400 minutes post-dose as a key time-point where doses of deguelin 
lead to both decreased (1.0 – 100 µM) and increased (0.01, 0.1 µM) oxygen 
consumption, we investigated the post-translational phosphorylation response to identify 
the underlying signal transduction events that allow for both decreased oxygen 
consumption and survival (ie. ~100% viability) at the 1.0 and 10 µM doses.  This method 
of selecting critical time-points of phosphorylation events from oxygen consumption data 
has been previously used by Boyd et al. (2012).   
 
4.3.3 Endogenous phosphorylation response to deguelin exposes a potential secondary 
therapeutic target  
 We next explored the signal transduction response, by means of post-translational 
phosphorylation activity, of HepG2 cells exposed to increasing doses of deguelin.  We 
simultaneously measured the phosphorylation of ERK1/2 (Thr202/Tyr204, 
Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα (Ser32/Ser36), JNK 
(Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK 
(Thr359/Ser363) at 400 minutes post-exposure to deguelin using bead-based ELISA flow 
cytometry.  These protein targets were selected because of their relevance in signal 
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transduction pathways related to cellular death and recovery [Dong et al., 2002; Jin and 
El-Deiry, 2005; Oren, 2003; Wilkinson and Millar, 2000], and due to the availability of 
selective inhibitors.  Figure 4.3 shows the relative phosphorylation response of HepG2 
cells to 400 minute exposures of increasing doses of deguelin (as compared to controls, 
normalized to a value of 1).  A two-way ANOVA with Bonferroni post-test determined 
significant differences (P < 0.05) between deguelin-exposed and control cells for 
p38MAPK at 0.1 µM; ERK1/2, JNK, p38MAPK, IκBα, p53, and p90RSK at 1.0 µM; for 
all proteins except JNK at 10 µM; and for all proteins at 100 µM (Figure 4.3).  While 
several proteins experienced a relative phosphorylation change in response to deguelin at 
400 minutes post-dose, p38MAPK phosphorylation is statistically different across four 
orders of magnitude of dose (1.0 – 100 µM).  
 
 
Figure 4.3. Relative phosphorylation of protein targets in response to 0.01 – 100 µM deguelin.  Post-
translational phosphorylation response of protein targets (from cell lysates) to 400 minute exposures of 
deguelin as outlined in Methods; responses are shown relative to control cells, which received dosing vehicle 
(<1% DMSO), but no deguelin.  The solid black line at y = 1 shows where observed post-translational 
phosphorylation responses are the same as control.  The phosphorylation responses found to be significantly 
different (P < 0.05) from controls are marked with *. 
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4.3.4 Using mixtures to suppress 
endogenous p38MAPK response to 
deguelin 
 To determine if our directed 
mixtures approach, which takes 
advantage of the endogenous 
pharmacodynamic response to 
deguelin, has the potential to 
decrease viability while minimizing 
deguelin’s effect on oxygen 
consumption, we attempted to 
suppress the post-translational 
p38MAPK phosphorylation 
response to deguelin by using a 
secondary inhibitor, SB202190.  We chose SB202190 because it is a selective inhibitor of 
p38MAPK (Lee et al., 1994).  HepG2 cells were exposed to SB202190 alone at its 
manufacturer reported IC50 (350 nM) and in combination with a full range of deguelin 
doses (0.01 – 100 µM), and we measured the p38MAPK post-translational 
phosphorylation response at 400 minutes post-dose (shown in Figure 4.4).  From this 
figure, SB202190 alone does decrease the phosphorylation response of p38MAPK (0.61 
± 0.02) when compared to controls, indicating that it is a relatively potent inhibitor (350 
nM) of p38MAPK.  A two-way ANOVA with Bonferroni post-test determined 
significant differences (P < 0.05) between the p38MAPK response to deguelin alone and 
Figure 4.4.  Relative p38MAPK phosphorylation in 
response to deguelin, SB202190, and mixtures of 
deguelin with SB202190. The phosphorylation response 
of p38MAPK from cell lysates at 400 minute exposures 
to mixtures of deguelin and 350 nM SB202190 (black), 
deguelin alone (white), and 350 nM SB202190 alone 
(black dots with grey line representing standard error of 
the mean) as discussed in sections 2.6 and 3.4; all values 
are reported as relative to control cells, which received 
dosing vehicle (<1% DMSO) only.  Error is reported as 
± SEM.  Post-translational phosphorylation responses of 
the mixture found to be significantly different (P < 0.05) 
from deguelin alone are marked with * and those 
different (P < 0.05) than SB202190 alone are marked 
with #. 
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Figure 4.5.  Percent viability of HepG2 cells in 
response to 24 hour exposure of deguelin alone and 
in combination with SB202190.  HepG2 viability in 
response to deguelin alone (triangles), mixtures of 
deguelin and 350 nM SB202190 (circles), and 350 nM 
SB202190 alone (black dotted line with grey shading 
for SEM). Viability, shown as % viability, was 
measured as outlined in section 2.4, and was calculated 
relative to control cells which received dosing vehicle 
(<1% DMSO), but no deguelin or inhibitor doses.  
Dose-response curves were generated by best-fit Hill-
plot regression of scatter plot data.  Mixture viability 
responses found to be significantly different (P < 0.05) 
from deguelin are marked with * and those different (P 
< 0.05) from SB202190 are marked with #.  
the mixture, as well as SB202190 alone and the mixture.  Most notably the relative 
p38MAPK phosphorylation responses to mixtures of deguelin (0.1 – 10 µM) with 
SB202190 were significantly decreased in comparison to deguelin alone.   
 
4.3.5 Mixtures approach retains efficacy while decreasing deguelin’s effect on O2 
consumption   
 To test this new potential therapeutic regimen, we exposed HepG2 cells to 
varying doses of deguelin (0.01-100 µM) in combination with SB202190 at its 
manufacturer reported IC50 (350 
nM) and measured viability (Figure 
4.5).  At 24 hours post-dose, 
viability was measured following 
treatment with SB202190 alone and 
in combination with deguelin 
(Figure 4.5), and compared to 
viability data for deguelin alone 
(controls measured concurrently).  
SB202190 alone did not 
significantly decrease viability at 
the 350 nM dose (98 ± 3 %).  
Viability was slightly decreased in 
response to mixtures of deguelin 
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(EC50 = 33 ± 1 µM) when compared to deguelin alone (EC50 = 45 ± 1 µM). To determine 
the effect of this mixtures technique on oxygen consumption, HepG2 cells were exposed 
to a full dosing regimen of deguelin (0.01 – 100 µM) in combination with SB202190 
(350 nM). Immediately after dosing, oxygen consumption was measured kinetically over 
24 hours and compared relative to controls, shown as percent oxygen consumption. From 
Figure 4.6, SB202190 alone did  not affect oxygen consumption from 0 – 600 minutes 
post-dose.  
However, after 600 minutes SB202190 decreased oxygen consumption.  Mixtures of 
deguelin (0.01 – 100 µM) with 350 nM SB202190 sustained oxygen consumption (100% 
Figure 4.6.  Percent 
oxygen consumption of 
HepG2 cells in response 
to deguelin alone, and 
in combination with 
SB202190.  Oxygen 
consumption response of 
HepG2 cells to 
SB202190 alone 
(squares), deguelin alone 
(triangles) and deguelin 
with 350 nM SB202190 
(circles) measured over 
24 hours.  Oxygen 
consumption was 
measured using 
MitoXpress extracellular 
assay as outlined in 
section 2.5.  Oxygen 
consumption is shown 
relative to control cells, 
which received dosing 
vehicle (<1% DMSO), 
but no deguelin or 
SB202190.  Oxygen 
consumption curves were 
generated using a best-fit 
polynomial function 
(solid line) with 
surrounding dotted lines 
reflecting the 95% 
confidence intervals.   
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oxygen consumption relative to controls) for 0.01 µM and 0.1 µM, or increased oxygen 
consumption (1.0 – 100 µM), whereas exposure to deguelin alone inhibited oxygen 
consumption at doses of 1.0 – 100 µM.  A Kruskal-Wallis nonparametric test with Dunns 
post-test was used to compare oxygen consumption responses between doses of deguelin 
alone and in combination with SB202190.  When compared to oxygen consumption in 
response to deguelin alone, mixture doses were statistically different (P < 0.05) for 1.0, 
10 and 100 µM.  When considering viability, efficacy of the highest mixture dose was 
sustained, while oxygen consumption at the highest mixture dose of deguelin (100 µM) 
with SB202190 was significantly increased (P < 0.05) when compared to 100 µM 
deguelin alone.  By increasing oxygen consumption using this endogenously-directed 
mixtures approach, we were able to successfully ameliorate an undesired alternative 
action of deguelin.   
 
4.4 Discussion 
 Due to the activity of various toxins at specific intracellular proteins, therapeutic 
agents derived from these toxins have been aggressively pursued (McCleary and Kini, 
2012).  One such example is cobrotoxin, a protein isolated from the venom of the Taiwan 
cobra Naja naja atra (Chang et al., 1997).  Cobrotoxin binds to nuclear factor-κB (NF-
κB) signaling molecules with high affinity, such as p50 and inhibitory κB kinases (IKKs) 
(Park et al., 2005).  Therapeutic agents capable of suppressing NF-κB are constantly 
being explored due to abnormal or constitutive NF-κB activity in many cancer types 
(Dolcet et al., 2005).  Cobrotoxin's inhibition of NF-κB signaling molecules suppresses 
NF-κB activity, making cobrotoxin an advantageous chemotherapeutic agent (Son et al., 
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2007).    From this ideology, the present proof of principle study has demonstrated that an 
endogenous response-directed mixtures approach may be useful for diminishing possible 
off-target effects while maintaining efficacy of naturally-derived potential therapeutics.  
Deguelin, a plant-derived chemopreventive agent, has been shown (Figure 4.1) to 
decrease HepG2 viability at high doses.  Previously, deguelin has been shown to alter 
activity at different intracellular proteins, such as AKT and HSP90 (Lee et al., 2005; Oh 
et al., 2007, 2008; Peng et al., 2007), making it a valid candidate for kinase-targeted 
chemotherapy.  However, deguelin has also been shown to affect mitochondrial 
bioenergetics, presumably due to its activity at complex I of the electron transport chain 
(Fang and Casida, 1998;Gerhauser, et al., 1997).  Previously, this inhibitory activity has 
been shown to decrease intracellular oxygen consumption in a mouse skin model 
(Gerhauser, et al., 1997), which may also contribute to cellular toxicity at distal cells.  
Our results (Figure 4.2) indicate that off-target inhibition of oxygen consumption was 
sustained over 24 hours in response to a range of doses (1.0 – 100 µM) of deguelin when 
it was used as a monotherapy.  While inhibition of oxygen consumption was sustained 
over a wide dosing range, a significant decrease in HepG2 viability occurs only at doses 
greater than 10 µM.  This suggests that deguelin’s inhibition of oxygen consumption may 
not be contributing to the decrease in HepG2 viability.  It is known from the Warburg 
Effect that cancer cells can utilize aerobic glycolysis for ATP production, whereas 
differentiated cells primarily produce ATP via oxidative phosphorylation that requires 
sufficient amounts of oxygen (Warburg, 1956).  In the absence of oxygen, it is difficult 
for differentiated cells to produce enough ATP from anaerobic glycolysis for survival, 
thus many undergo apoptosis under hypoxic conditions.  However, cancer cells, such as 
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HepG2, can survive in an oxygen-deficient environment due to their reliance on aerobic 
glycolysis to produce ATP [for a review, see Vander Heiden et al., 2009].  Therefore, the 
Warburg Effect, in conjunction with our results, supports that deguelin’s activity at 
separate intracellular sites may be causing decreased viability, whereas inhibition of 
oxygen consumption is possibly an undesirable alternative activity of deguelin that limits 
its usefulness as a possible therapeutic (Lee et al., 2005; Oh et al., 2007, 2008).   
To better understand the discrepancies in HepG2 viability and oxygen 
consumption in response to deguelin, we investigated the post-translational 
phosphorylation response of several key proteins involved in cell recovery or pro-
apoptotic signaling cascades (Figure 4.3).  We found that p38MAPK phosphorylation in 
response to deguelin is significantly different over several orders of magnitude (0.1 – 100 
µM) of dose.  For 0.1 – 10 µM doses of deguelin, the relative phosphorylation response 
of p38MAPK is significantly increased.  With regard to HepG2 viability, the 0.1 – 10 µM 
dosing range is ineffective, indicating p38MAPK as a possible protein involved in an 
endogenous defense mechanism that improves survival against deguelin.  This is further 
supported by the decrease in relative phosphorylation of p38MAPK in response to 100 
µM dose of deguelin that coincides with decreased viability at this dose, indicating the 
cell may not be able to effectively respond to a high dose of deguelin.  This preliminary 
data suggests that a directed mixtures approach utilizing p38MAPK as a secondary target, 
thereby capitalizing on the endogenous response to deguelin, may be advantageous.  
However, it should be noted that due to the limited number of proteins measured in this 
study, there may be activity at other proteins/cascades that could be influencing the 
overall pharmacodynamic response to deguelin. 
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While monotherapies for cancer have proven to be successful when a single target 
controls the cell’s fate, many carcinomas are often more complex, with intricate signaling 
networks governing proliferation (Toschi and Janne, 2008).  This complex survival 
framework, capable of facilitating uncontrolled proliferation, can withstand the inhibition 
of a single target by switching to an alternate mode for survival.  However, by utilizing 
the endogenous response to a single insult (primary therapeutic), a second inhibitor may 
be used as a mixture with the primary therapeutic for a more effective treatment.  
Combinatorial approaches have previously been shown to improve various cancer 
therapies (Engelman et al., 2007; Fitzgerald et al., 2006; Ma et al., 2005; Namiki et al., 
2006; Stommel et al., 2007; Toschi and Janne, 2008; Yasui et al., 2007).  To this end, we 
combined a selective p38MAPK inhibitor, SB202190, with deguelin to suppress the 
endogenous p38MAPK response to deguelin alone (Figure 4.4). Additionally, when used 
as a therapeutic mixture, efficacy of deguelin was maintained (Figure 4.5). While 
SB202190 has been shown to be a selective p38MAPK inhibitor, we recognize that 
inhibitors are not perfect and may alter the activity of undesired intracellular proteins 
(Muniyappa and Das, 2008).  Additionally, SB202190 has been shown to be toxic in a 
human leukemia cell line 24 hours post-exposure at higher doses (50 μM) (Nemoto et al., 
1998). In this study, we found that SB202190 (350 nM) alone did not significantly 
decrease HepG2 viability 24 hours post-exposure (Figure 4.5).  It should be noted that the 
diverse role of p38MAPK signaling, for example the conflicting results during 
ischemia/reperfusion injury (for review, see Steenbergen, 2002), after cellular stress or 
xenobiotic exposure can vary based on the model system used (Cuadrado and Nebreda. 
2010).          
138 
 
By using this directed mixtures approach, the undesired alternative action of 
deguelin (inhibition of oxygen consumption) can be ameliorated without sacrificing 
efficacy.  From Figure 4.6, SB202190 treatment alone decreased oxygen consumption 
slightly, but treatment with the various mixtures led to an increase in oxygen 
consumption when compared to deguelin alone, thus minimizing deguelin’s undesired 
effect on oxygen consumption.  Most notably, the highest mixture dose showed an 
increase in oxygen consumption when compared to 100 µM of deguelin alone, while 
maintaining efficacy (less than 15% viability).  These results are consistent with previous 
studies that monitored mitochondrial bioenergetics in response to ETC inhibitors (Arvier 
et al., 2007; Dumas et al., 2003; Roussel et al., 2003).  Desquiret and coworkers (2008) 
found that dexamethasone, a synthetic glucocorticoid, inhibits mitochondrial activity 
(specifically complex I and II) in HepG2 cells. Since glucocorticoid stimulation activates 
G protein-coupled receptor (GPCR), they hypothesized that GPCR mediated kinase 
pathways may be key players in regulating rapid glucocorticoid activity at ETC 
complexes. From this, they co-exposed HepG2 cells to dexamethasone and SB202190 
(since p38MAPK is downstream of GPCR), and found that SB202190 increased 
Complex I activity by 80%, when compared to HepG2 cells exposed to dexamethasone 
alone, which demonstrates the vital role p38MAPK plays in mediating mitochondrial 
bioenergetics after xenobiotic exposure. By using our proposed mixtures approach, the 
undesired alternative action of deguelin (inhibition of oxygen consumption) was 
diminished by inhibiting p38MAPK. 
As a proof of principle, the novel mixtures approach presented here exploits the 
endogenous intracellular response to a primary therapeutic, revealing a secondary target 
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for a combinatorial therapeutic regimen. By using this endogenously selected mixture, 
the cell’s native response mechanism against a primary therapeutic is inhibited, making 
the intracellular signaling network less effective at cell recovery and decreasing viability.  
From this directed mixtures approach, a primary therapeutic’s efficacy can be 
maintained, while potentially decreasing undesired side effects.  Additionally, by using 
this approach, previously unsuccessful therapeutics derived from toxins can be revisited.  
This ultimately speaks to the significance of pharmacodynamic mixtures that target 
kinase responses as an avenue of future research.    
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5. Future directions: Expanding concepts to human interaction 
 The work presented in this dissertation was meant to understand early cellular 
changes, whether that be alterations in cellular bioenergetics or pathway perturbations, 
and use the resulting mechanistic information to formulate new toxicity prediction 
models. With better prediction models that harness the mechanistic information from well 
planned, high-throughput in vitro experiments, many more individual chemicals and 
mixtures can be properly assessed for toxicity risk assessment. The success of the 
prediction models presented in this dissertation may greatly impact xenobiotic high-
throughput mixtures risk assessment in vitro, as well as pharmaceutical adverse drug 
reaction analyses. Additionally, this fundamental research may be expanded to human 
research interaction studies, where intercommunication and team dynamics may 
contribute to responses of individuals on a team (human mixtures). Preliminary research 
regarding this new application is presented in this chapter. 
 
5.1 Introduction 
 Perturbations of biological processes by chemical stress exposure can elicit early 
cellular changes, leading to an adaptive stress response for continued survival or adverse 
response leading to toxicity (Andersen, 2010). The term "stress" is not exclusive to 
exogenous xenobiotics, but also extends to external stimuli that initiate endogenous stress 
signaling biomolecules, such as cytokines, hormones, and catecholamines, to name a few 
(Boelsterli, 2007). In light of this classification, the same high-throughput approach for 
measuring xenobiotic chemical stress for individual compounds or chemical mixtures 
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may be applied to human interaction studies to understand the dynamic molecular 
response to social stress and teamwork. With this approach, teams can be constructed to 
reduce individual "stress," improve teamwork, and develop models incorporating human 
interaction stress responses for risk assessment.    
 In the presence of stress-inducing stimuli, there is bimodal communication between 
the brain and body, which is coordinated by the autonomic nervous system (ANS), endocrine 
and immune systems (McEwen, 2005; McEwen, 2007). This bimodal communication relies 
on dynamic chemical messengers released to promote adaptation (allostasis) in response to 
environmental, psychological, and physiological stressors (Chida and Hamer, 2008). The 
initiation of these messengers can be measured as early as seconds to minutes after an 
individual perceives a situation or stimuli as a threat (Sapolsky et al., 2000). The perception 
of threat and allostatic responses to external stimuli, whether they are real or imagined, can 
vary depending upon individual inherent (genetic makeup or development), behavioral 
(lifestyle choices and mechanisms for coping), and historical (previous trauma or major life 
events) factors (McEwen, 1998; Juster et al., 2010). These components drive individual 
resiliency or sensitivity to stress. Sensitivity to repeated acute stressors over time can lead to 
chronic stress and disease states. The Allostatic Load (AL) model has been used over the last 
two decades to better understand the physiology of stress, especially as it relates to effects of 
stress in the workplace and at home (McEwen and Stellar, 1993; Ganster and Rosen, 2013). 
The AL model has numerous potential applications for various fields of study to monitor 
individuals and teams that are under substantial amounts of stress, whether it be medical 
(doctors, nurses, paramedics), business and management (market traders, both small and 
large companies), athletic teams, or military units.       
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 Research investigating social relationships as they relate to physical health has 
been well documented (House et al., 1988; Umberson and Montez, 2010). Supportive 
relationships and interactions have been shown to improve immune, endocrine, and 
cardiovascular responses to stress and reduce overall AL (Cohen, 2004; Kiecolt-Glaser et 
al., 2005). With this in mind, allostatic responses to a perceived threat, competition, or 
risk taking may be different when a task is performed as a team rather than an individual.  
 In the presence of acute stress-inducing stimuli, the AL model proposes the 
following mechanism for primary processes for initial adaptation to stress. Primary 
processes of the AL model include psychological (fear or anxiety), physiological 
(cortisol, catecholamines, cytokines), and psychosomatic (fatigue or sleep disturbance) 
mediators (McEwen, 2003; Ganster and Rosen, 2013). Recent trends in AL research 
suggest moving away from single biomarkers to a more inclusive and comprehensive 
multiplex approach (Khan, 2012; Ganster and Rosen, 2013), casting a wide net on 
multiple physiological pathways (neuroendocrine, immune, metabolic, and 
cardiovascular) to elucidate an individual's acute and/or chronic stress response, similar 
to the recent NRC report suggestions (NRC, 2007).  
 To this end, we initiated a human research study to monitor individual and team 
physiological metrics and elucidate adaptive biomolecular responses relevant to 
teamwork stress and performance. In this study, we enrolled Air Force Reserve Officers’ 
Training Corps (ROTC) cadets to perform a mock hostage rescue mission alone and as 
part of a four person team. During the study, we measured an array of salivary 
biomarkers related to the various pathways of an individual's stress response for potential 
elucidation of the major and minor physiological mediators driving adaptive stress 
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responses while on a team. We hypothesized that individual salivary responses would 
increase as part of a team, due to increased demands and forced social interaction to 
complete a task. This work opens the door for a new avenue of mixtures research, where 
interaction with other individuals in combination with emotional, physical, or chemical 
exposure, can be considered as a component that may alter an individual’s response. 
 
5.2 Materials and Methods 
5.2.1 Subjects  
The present study enrolled 17 subjects (18-22 y of age) from West Virginia 
University’s Air Force Reserve Officers’ Training Corps (ROTC). Subjects were 
introduced to the study during a university ROTC course, where the background 
rationale, goals and risks were described in a power point presentation. Those in 
attendance who were interested in participating were asked to provide their email address 
to contact about availability for the study and to go over consent. A total of 17 subjects 
were originally enrolled in the study (16 male, 1 female). After the individual phase of 
the study, where subjects performed the tasks alone, one subject was dropped from the 
study due to sampling errors. A total of 16 subjects (15 male, 1 female) were used for the 
team portion of the study. Subjects were placed on teams using a random number 
generator and their schedule availability. This study received approval from the 
Institutional Review Board committee at West Virginia University and the United States 
Army Medical Research and Materiel Command (USAMRMC) Office of Research 
Protections. 
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5.2.2 Salivary biomarkers 
Saliva samples were collected immediately (less than 5 minutes) before the 
mission clock started. Samples were collected with saliva collection aids purchased from 
Salimetrics (State College, PA). All subjects had refrained from eating at least one hour 
prior to sample collection. Unstimulated saliva samples were collected using the passive 
drool method. Saliva samples were stored on ice (less than 3 h) before centrifugation (to 
remove saliva debris) and long-term storage at -80°C. Salivary cytokines were assayed 
using commercial kits. Salivary cytokines (GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-8, IL-10 and TNF-α), were assayed using a commercial magnetic bead-based 
suspension array 10-plex cytokine kit (cat. no. LHC0001M) purchased from Life 
Technologies (Carlsbad, CA). Assay was performed in triplicate (25 µL/assay well) 
according to manufacturer's protocol and measured with a Bio-plex 200 platform (Bio-
Rad, Hercules, CA). All samples (individual and team) analyzed with cytokine kits were 
assayed over the course of a week.        
 
5.3 Results and Discussion 
The human body, especially endocrine, immune, and cardiovascular system, is 
exceedingly sensitive and responsive to social interactions (Heaphy and Dutton, 2008). 
These social interactions, whether they are with peers or those higher/lower in 
employee/team status, can have a substantial impact on workplace efficiency, 
performance, and, potentially, workplace-induced stress. As a key player in immune 
surveillance and response, the mouth is in constant contact with airborne pollutants that 
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are bacterial, viral, or chemical in nature (O'Connor et al., 2009).  To gain a better 
understanding of team dynamics and the impact of teamwork on an individual, we 
compared initial salivary cytokine responses when subjects performed our mock hostage 
rescue mission as an individual to initial salivary cytokine responses when they 
performed it as part of a team. As an individual, subjects' initial summed salivary 
cytokine responses (IL-1β, IL-10, IL-6, GM-CSF, IL-5, IFN-γ, TNF-α, IL-2, and IL-4) 
were lower than when performing the mission as part of a four person team (Figures 5.1-
2), with the exception of subject 4; thus agreeing with our hypothesis that the team 
scenario would induce higher initial salivary cytokine levels than when they arrived to 
perform the mission as an individual.  
 
Additionally, subjects' summed salivary cytokine levels were significantly 
different when comparing individual and team responses (P < 0.01, paired student's t-
test). However, in relation to performance, the time to complete the mock hostage rescue 
mission as an individual (Table 5.1) was not significantly correlated to any single or  
Figure 5.1 Initial salivary cytokine 
responses as an individual. Salivary 
samples were collected via passive drool 
method less than 5 minutes before the first 
mission started for the individual portion 
of the study. Samples were assayed using 
the multiplex bead-based ELISA. 
Horizontal line represents mean for the 4 
individuals on their eventual team 
(organized by team to easier 
visualization). Error bars represent S.E.M. 
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summed salivary cytokine response (Table 5.2). This relation was also true for initial 
salivary cytokine concentrations when performing the mission as part of a team.   
The mechanism driving salivary cytokine responses after social interaction 
exposure has yet to be elucidated. The whole-organism signaling response (intra- and 
inter- cellular, as well as disparate organ system communication) involves a complex 
spatiotemporal coordination of multiple components, whether they be proteins or 
biomolecules, to integrate the stressful stimuli and produce a response. Neural-immune 
(e.g, brain-cytokine) communication between the immune system and the central nervous 
system (CNS) involves the coordination of many key players, such as the vagus, 
glossopharyngeal, and trigeminal nerves, HPA axis, SNS, peripheral nervous system 
Figure 5.2 Initial salivary cytokine 
responses as a team. Salivary samples 
were collected via passive drool 
method less than 5 min before the first 
mission of the team portion of the 
study. Samples were assayed using the 
multiplex bead-based ELISA. 
Horizontal line represents mean for the 
4 individuals on a team (during the 
team portion of the study). Error bars 
represent S.E.M. 
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(PNS), and their corresponding downstream targets (tissues and organs) (Romeo et al., 
2001; Navarro et al., 2006; Thayer and Sternberg, 2010). The parasympathetic nervous 
system (both afferent and efferent activity) in particular has been shown to be a major 
player in neural-immune communication (Sternberg, 2006). It has been suggested that the 
vagus nerve is highly innervated with IL-1 receptors (Goehler et al., 1997), and the 
presence of afferent branches of vagus nerve (pharyngeal and laryngeal) in the mouth and 
pharynx, as well as the overall gustatory system (Berthoud, 2008), may act as sensory 
nerves for salivary IL-1β related to local immune responses or social and psychological 
stressors. In addition to the vagus nerve, immune to brain communication may be relayed 
by glossopharyngeal nerve afferents present in the posterior oral cavity (Watkins and 
Maier, 2005; Goehler, 2008). In a study relating the glossopharyngeal nerve and immune 
to brain communication, rats that underwent a bilateral glossopharyngeal nerve 
transection were exposed to either lipopolysaccharide (LPS) or IL-1β via injection into 
the soft palate (ISP) (Romeo et al., 2001). Sham rats exposed to LPS or IL-1β via ISP 
showed a febrile dose-response. However, rats with bilateral glossopharyngeal nerve 
transection had a reduced febrile response after LPS or IL-1β exposure, suggesting the 
critical role of the glossopharyngeal nerve for immune to brain communication from the 
oral cavity. The trigeminal nerve is also a key player in immune to brain communication. 
The trigeminal nerve provides afferent somatosensory innervation to the face and oral 
cavity in mammals (Byers and Dong, 1989). To investigate the relationship between 
acute oral inflammation and brain communication, Navarro and colleagues (Navarro et 
al., 2006) injected LPS into periodontal tissue and measured their febrile response. They 
found that local periodontal inflammation induced a febrile response and maxillary 
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trigeminal nerve transection attenuated this febrile response, suggesting the trigeminal 
nerve is involved in oral inflammation to brain communication.  
 
5.4 Conclusion 
Military teams experience work environments that are both dynamic and 
complex, under potentially life threatening circumstances, which indicates a high 
workload (Cannon-Bowers et al., 1992; Urban et al., 1995). Even though these military 
units undergo advanced physical and mental training in preparation for future missions, 
performance may decline when it is most critical (i.e., during a mission) (Sandal et al., 1998). 
Selection of a team that will withstand and adapt to any external stressors and work as a 
cohesive unit toward mission success is imperative; both metrics and methods for selecting 
these individuals are needed. In this study, we have shown that for a mock hostage rescue 
mission in an urban setting, summed initial salivary cytokine responses increase when the 
mission was performed with teammates as opposed to individually, suggesting a relationship 
between potential social stress and salivary cytokines. 
 
5.5 References 
Andersen, M.E., 2010. Calling on science: making "alternatives" the new gold standard. 
ALTEX 27, 29-37. 
 
Berthoud, H.R., 2008. The vagus nerve, food intake and obesity. Regul Pept 149, 15-25. 
 
Boelsterli, U.A., 2007. Mechanistic Toxicology: The Molecular Basis of How Chemicals 
Disrupt Biological Targets, Second Edition. CRC Press, Boca Raton, FL. 
 
155 
 
Byers, M.R., Dong, W.K., 1989. Comparison of trigeminal receptor location and 
structure in the periodontal ligament of different types of teeth from the rat, cat, 
and monkey. J Comp Neurol 279, 117-127. 
 
Cannon-Bowers, J.A., Oser, R., Flanagan, D.L., 1992. Work teams in industry: A 
selected review and proposed framework. Ablex Publishing, Norwood, NJ. 
 
Chida, Y., Hamer, M., 2008. Chronic psychosocial factors and acute physiological 
responses to laboratory-induced stress in healthy populations: a quantitative 
review of 30 years of investigations. Psychol Bull 134, 829-885. 
 
Cohen, S., 2004. Social relationships and health, Am Psychol, United States, pp. 676-
684. 
 
Ganster, D.C., Rosen, C.C., 2013. Work stress and employee health: A multidisciplinary 
review. Journal of Management 39, 1085-1122. 
 
Goehler, L.E., 2008. Cytokines in Neural Signaling to the Brain.  6, 337–352. 
 
Goehler, L.E., Relton, J.K., Dripps, D., Kiechle, R., Tartaglia, N., Maier, S.F., Watkins, 
L.R., 1997. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: 
a possible mechanism for immune-to-brain communication. Brain Res Bull 43, 
357-364. 
 
Heaphy, E.D., Dutton, J.E., 2008. Positive Social Interactions and the Human Body at 
Work: Liking Organizations and Physiolgy. Academy of Management Review 33, 
137-162. 
 
House, J.S., Landis, K.R., Umberson, D., 1988. Social relationships and health. Science 
241, 540-545. 
Juster, R.P., McEwen, B.S., Lupien, S.J., 2010. Allostatic load biomarkers of chronic 
stress and impact on health and cognition. Neurosci Biobehav Rev 35, 2-16. 
 
Khan, A., 2012. Detection and quantitation of forty eight cytokines, chemokines, growth 
factors and nine acute phase proteins in healthy human plasma, saliva and urine. J 
Proteomics 75, 4802-4819. 
 
Kiecolt-Glaser, J.K., Loving, T.J., Stowell, J.R., Malarkey, W.B., Lemeshow, S., 
Dickinson, S.L., Glaser, R., 2005. Hostile marital interactions, proinflammatory 
cytokine production, and wound healing. Arch Gen Psychiatry 62, 1377-1384. 
 
McEwen, B.S., 1998. Stress, adaptation, and disease. Allostasis and allostatic load. Ann 
N Y Acad Sci 840, 33-44. 
 
McEwen, B.S., 2003. Interacting mediators of allostasis and allostatic load: towards an 
understanding of resilience in aging. Metabolism 52, 10-16. 
156 
 
 
McEwen, B.S., 2005. Stressed or stressed out: what is the difference? J Psychiatry 
Neurosci 30, 315-318. 
 
McEwen, B.S., 2007. Physiology and neurobiology of stress and adaptation: central role 
of the brain. Physiol Rev 87, 873-904. 
 
McEwen, B.S., Stellar, E., 1993. Stress and the individual. Mechanisms leading to 
disease. Arch Intern Med 153, 2093-2101. 
 
Navarro, V.P., Iyomasa, M.M., Leite-Panissi, C.R., Almeida, M.C., Branco, L.G., 2006. 
New role of the trigeminal nerve as a neuronal pathway signaling brain in acute 
periodontitis: participation of local prostaglandins. Pflugers Arch 453, 73-82. 
 
NRC, 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. National 
Academies Press, Washington, D.C. 
 
O'Connor, M.F., Irwin, M.R., Wellisch, D.K., 2009. When grief heats up: pro-
inflammatory cytokines predict regional brain activation. Neuroimage 47, 891-
896. 
 
Romeo, H.E., Tio, D.L., Rahman, S.U., Chiappelli, F., Taylor, A.N., 2001. The 
glossopharyngeal nerve as a novel pathway in immune-to-brain communication: 
relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 115, 
91-100. 
 
Sandal, G.M., Gronningsaeter, H., Eriksen, H.R., Gravraakmo, A., Birkeland, K., Ursin, 
H., 1998. Personality and endocrine activation in military stress situations. 
Military Psychology 10, 45-61. 
 
Sapolsky, R.M., Romero, L.M., Munck, A.U., 2000. How do glucocorticoids influence 
stress responses? Integrating permissive, suppressive, stimulatory, and preparative 
actions. Endocr Rev 21, 55-89. 
 
Sternberg, E.M., 2006. Neural regulation of innate immunity: a coordinated nonspecific 
host response to pathogens. Nat Rev Immunol 6, 318-328. 
 
Thayer, J.F., Sternberg, E.M., 2010. Neural aspects of immunomodulation: focus on the 
vagus nerve. Brain Behav Immun 24, 1223-1228. 
 
Umberson, D., Montez, J.K., 2010. Social relationships and health: a flashpoint for health 
policy. J Health Soc Behav 51 Suppl, S54-66. 
 
Urban, J.M., Bowers, C.A., Monday, S.D., Morgan Jr., B.B., 1995. Workload, team 
structure, and communication in team performance. Military Psychology 7, 123-
139. 
157 
 
 
Watkins, L.R., Maier, S.F., 2005. Immune regulation of central nervous system functions: 
from sickness responses to pathological pain. J Intern Med 257, 139-155. 
